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1SUMMARY
Polylactosaminoglycans (PLGs) are
composed of N-acetyllactosamine
disaccharide units, and they form the
sugar backbones of many glyconjugates.
Their structures vary from linear to
highly branched, with their degree of
branching being dependent on the stage
of development and differentiation of the
given organism or cell type. PLGs, which
are linked to cell surface proteins and
lipids, carry terminal decorations
responsible for their biological functions.
N-acetylgalactosamine sometimes
replaces the terminal galactose of PLG,
resulting in N,N-diacetyllactosdiamine,
which can be decorated similarly to N-
acetyllactosamine. Internal N,N-
diacetyllactosdiamines have not been
encountered in naturally occurring PLGs.
In this study, we have shown that an
enzyme activity present in human serum
elongates PLGs containing terminal N,N-
diacetyllactosdiamine, suggesting that
this disaccharide unit may occur
internally in natural PLGs. These novel
glycans can function as acceptors for
mammalian glycosyltransferases. In
addition, a method was developed to
identify naturally occurring internal N,N-
diacetyllactosdiamines.
Sialyl Lewis x (sLex) antigen
[NeuNAcα2,3Galβ1-4(Fucα1-3)GlcNAc],
a terminal decoration of PLGs, plays an
important role in adhesion of leukocytes
to endothelial cells. Branched PLGs
carrying multiple sLex antigens can be
used to inhibit this adhesion to, for
example, prevent organ transplant
rejection. To synthesize these for use as
therapeutics, three mammalian enzymes
were produced as recombinant proteins.
PLG branching enzyme (IGnT6) was
expressed in insect cells. It branched
linear PLG at internal positions
exhibiting centrally acting branching
activity (cIGnT6), which could be used to
synthesize multivalent inhibitors of
leukocyte adhesion. Rat α2,3-
sialyltransferase and human α1,3-
fucosyltransferase VII were expressed in
the yeasts Saccharomyces cerevisiae and
Pichia pastoris. Their ectodomains were
expressed as fusion proteins, which were
secreted but remained bound to the yeast
cell wall. This enabled the use of intact
yeast cells as a source of enzymatic
activity for the synthesis of sLex. Yeasts
expressing the two enzymes either in
separate strains or in a single strain
functioned in tandem in the synthesis of
sLex. The recombinant proteins were
expressed under the control of the
HSP150 promoter, the strength of which
was found to be comparable with strong
well-known yeast promoters.
Summary
21. INTRODUCTION
1.1. Structure and biosynthesis of ordinary polylactosaminoglycans
Polylactosaminoglycans form linear or
branched sugar backbones (Fig. 1) of
many glycoconjugates, including N- and
O-glycans of glycoproteins, some
glycolipids (reviewed in Leppänen,
1997) (see Fig. 2 for common core
structures), and keratan sulfate
proteoglycan (Brown et al., 1994a,
1994b; Greiling, 1994). The linear
backbones are composed of repeating
disaccharide units, either Galâ1-
4GlcNAc (N-acetyllactosamine, lacNAc)
(type 2 lacNAc) or Galâ1-3GlcNAc (type
1), which are joined by â1,3-linkages.
The branched variations carry â1,6-
linked GlcNAc units at some 3-
substituted galactose residues, and these
GlcNAc branches can be further
elongated and branched. The linear and
branched sugar backbones are often
referred to as i- and I-type polylactos-
aminoglycans, respectively, because they
represent blood group i- and I-antigens
(Feizi et al., 1979; Fukuda et al., 1979).
The termini of the linear backbones
and the branches are the carriers of the
terminal structures. These terminal
structures are diverse, for example, the
terminal galactose can be á2,3- or á2,6-
sialylated, sulfated at carbon 3 or 6, or
can carry an á1,3-linked galactose.
Terminal decorations also include ABO-
blood group antigens and so-called Lewis
antigens (Fig. 3).
The biological functions of
glycoconjugates are mostly carried out by
these terminal structures. They, for
instance, serve as ligands for distinct
lectins (carbohydrate-binding proteins)
and they function as cell adhesion
molecules (Rosen and Bertozzi, 1994).
One important goal in enzymatic
Figure 1. Linear (i-type) and branched (I-type) lactosaminoglycan.
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3oligosaccharide synthesis is to produce
oligosaccharides carrying these binding
epitopes in order to use them as counter
receptors and antagonists of animal
lectins to prevent certain cell adhesion
events such as those involved in vascular
biology and fertilization.
The linear i-type blood group
antigen is synthesized by sequential
action of â1,3-N-acetylglucosaminyl-
transferase (â1,3GlcNAcT) and â1,4-
galactosyltransferase (â1,4GalT). The i-
antigens are converted to I-antigens by
yet another enzyme, â1,6-N-acetyl-
glucosaminyltransferase (IGnT). Two
distinct branching IGnT activities have
been described in vitro. The “distally”
acting dIGnT transfers a â1,6-GlcNAc
unit to the penultimate galactose of linear
polylactosaminoglycan, acting
coordinately with the elongation enzymes
mentioned above (Piller et al., 1984;
Brockhausen et al., 1986; Koenderman et
al., 1987; Seppo et al., 1990; Gu et al.,
1992; Helin et al., 1997). This results in
complex branches, which are further
elongated and branched. The “centrally”
acting cIGnT transfers a GlcNAc unit to
the internal galactose of the preformed
linear polylactosaminoglycan (Leppänen
et al., 1991, 1997, 1998; Gu et al., 1992),
resulting in multiple short branches along
the polylactosaminoglycan chain.
Figure 2. Examples of common core structures.
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4Figure 3. Structures of several terminal antigenic epitopes.
1.2. N-Acetylgalactosaminyl (GalNAc) analogs of ordinary
polylactosaminoglycans
In an increasing number of cases,
GalNAcâ1-4GlcNAc (N,N-diacetyl-
lactosdiamine, lacdiNAc), an analog of
lacNAc, has been found to replace the
lacNAc unit in polylactosaminoglycan
backbones in complex-type glycans of
glycoproteins and glycolipids (reviewed
in van den Eijnden et al., 1997).
LacdiNAc-containing sugar chains occur
on vertebrate, including mammal, and
invertebrate glycoconjugates (see Table 1
for structures and references). The
lacdiNAc unit replaces the nonreducing
lacNAc and can be terminally substituted
analogously to terminal lacNAc motifs.
The group of glycoconjugates carrying
these chains is diverse, consisting of
hormones, transport proteins, enzymes,
and protective glycoproteins. Despite the
wide variety of terminal structures
involving the lacdiNAc determinant,
truly internal lacdiNAc sequences in
polylactosaminoglycans have not been
reported. The GlcNAcâ1-3GalNAc
bond is, however, known among
glycoconjugates. O-glycan core 3
contains a GlcNAcâ1-3GalNAc linkage
(Brockhausen et al., 1985), and human
blood fluke Schistosoma mansoni
cercarial glycolipids are known to carry
GlcNAcâ1-3GalNAc-containing glycans
(Wuhrer et al., 2000).
Introduction
51.2.1. Structures
In the 1980s, the Asn-linked
oligosaccharides of the mammalian
pituitary hormone lutropin were found to
contain N-acetylgalactosamine as a
building block (Bahl et al., 1980; Parsons
and Pierce, 1980; Bedi et al., 1982).
Several different structures for these
glycans were proposed, but due to the
lack of specific methods for
characterization, the exact structures
were not revealed until 1985 (Green et
al., 1985). Since then, interest in these
structures has increased, and as a result of
extensive research, the list of known
glycoconjugates carrying lacdiNAc-
containing glycans is quite impressive.
Table 1 displays the terminal structures
and the occurrence of these glycans,
while the structural elucidation of the
corresponding glycoconjugate is
presented in the reference.
1.2.2. Biosynthesis of
GalNAcâ1-4GlcNAc units
There are two kinds of enzymatic â1,4-
N-acetylgalactosaminyltransferase (â1,4-
GalNAcT) activities known to synthesize
lacdiNAc disaccharide structures, that
differ from each other by the ability/
disability to recognize the underlying
polypeptide chain. The most studied
example is the synthesis of sulfated
oligosaccharides containing the
lacdiNAc motif on glycoprotein
hormones (see Table 1 for structures); the
synthesis is highly specific and tightly
regulated. Thus, the presence of sulfated
oligosaccharides suggests that they play
an important role in the biologic behavior
of these hormones. Two of the hormones,
lutropin (LH) and follitropin (FSH), are
synthesized within the same cells in the
pituitary. Yet LH carries N-linked
oligosaccharides with terminal SO
4
-
4GalNAcâ1-4GlcNAcâ1-2Maná
structures, whereas N-glycans of FSH are
decorated with NeuNAcá2,3Galâ1-
4GlcNAcâ1-2Maná terminal structures
(Green and Baenziger, 1988a, 1988b).
The oligosaccharide intermediates of
these glycans are identical so the N-
ace ty lga lac tosaminy l t r ans fe rase
responsible for catalyzing the addition of
GalNAc rather than Gal to the
oligosaccharide chain has to recognize
features of the underlying polypeptide
chain in addition to the oligosaccharide
acceptor. Smith and Baenziger (1988)
discovered glycoprotein hormone-
specific GalNAc transferase (â1,4-
GalNAcT) in bovine interior pituitary
membranes which transfers GalNAc to
the terminal GlcNAc of
GlcNAc
2
Man
3
GlcNAc
2
Asn, and they
proposed that recognition by the â1,4-
GalNAcT requires the Pro-Xaa-Arg/Lys
motif (where Xaa is a hydrophobic amino
acid), located 6-9 residues on the amino-
terminal side of an asparagine
glycosylation site (Smith and Baenziger,
1992). This peptide-recognition marker is
not present on the â-subunit of FSH,
which explains the absence of N-linked
oligosaccharides containing GalNAc on
this glycoprotein hormone (Smith and
Baenziger, 1992). Pro-Xaa-Arg/Lys
peptide recognition marker is also
present in glycoprotein hormone
thyrotropin (Hiyama et al., 1992), pro-
opiomelanocortin (Skelton et al., 1992),
and tissue factor pathway inhibitor
(Smith et al., 1992). Each of these
glycoproteins carries Asn-linked
oligosaccharides with the terminal SO
4
-
4GalNAcâ1-4GlcNAcâ1-2Maná
sequence. The presence of the peptide
recognition marker on glycopeptide
substrates reduces the apparent K
m
 of
glycoprotein hormone-specific β1,4-
Introduction
6Terminal structure Occurrence Reference
GalNAcβ1-4GlcNAc Bovine ?-lactalbumin Tilley et al. , 1991 
Bovine milk fat globule membrane proteins Sato et al. , 1993
Bovine milk butyrophilin Sato et al. , 1995
Bovine milk IgG heavy chain Aoki et al. , 1995 
Bovine milk phosphoglycoprotein PP3 Girardet et al. , 1995 
Bovine parotid gland carbonic anhydrase VI Hooper et al. , 1995 
Human urinary kallidinogenase Tomiya et al. , 1993 
Human urokinase Bergwerff et al. , 1995 
Human glycodelin A Dell et al. , 1995 
Snake venom serine protease (batroxobin) Lochnit and Geyer, 1995 
Schistosomal glycoproteins Srivatsan et al. , 1992 
Dirofilaria immitis (dog heartworm) Kang et al. , 1993 
Rnase 1 from Capan-1 tumor cells Peracaula et al. , 2003 
Honeybee royal jelly glycoprotein Kimura et al. , 2002 
Matrix metalloproteinase-1 (HT-1080 fibrosarcoma cells) Saarinen et al. , 1999 
NeuAc?2-3GalNAc?1-4GlcNAc Snake venom serine protease (ancrod) Pfeiffer et al. , 1992 
Snake venom serine protease (batroxobin) Tanaka et al. , 1992 
NeuAc?2-6GalNAc?1-4GlcNAc Pituitary hormones Weisshaar et al. , 1991 
Bovine lactotransferrin Coddeville et al. , 1992 
Bovine mammary epithelial CD36 Nakata et al. , 1993 
Bovine milk phosphoglycoprotein PP3 Girardet et al. , 1995 
Human urokinase Bergwerff et al. , 1995 
Human glycodelin A Dell et al. , 1995 
Recombinant human protein C Yan et al. , 1993 
Recombinant tissue plasminogen activator Chan et al. , 1991 
Rat placental prolactin family Manzella et al. , 1997 
SO4-4GalNAc?1-4GlcNAc Pituitary hormones Baenziger and Green, 1988;
 Hiyama et al., 1992 
Bovine pro-opiomelanocortin Siciliano et al. , 1994 
Bovine submaxillary gland carbonic anhydrase VI Hooper et al. , 1995 
Human Tamm-Horsfall glycoprotein Hård et al. , 1992 
Human urokinase Bergwerff et al. , 1995 
Recombinant tissue factor pathway inhibitor Smith et al. , 1992 
Murine pro-opiomelanocortin Skelton et al. , 1992 
Cellular adhesion molecule Tenascin-R Woodworth et al. , 2002 
GalNAc?1-4(Fuc?1-3)GlcNAc Bovine pro-opiomelanocotin Siciliano et al. , 1993 
Human urokinase Bergwerff et al. , 1995 
Human glycodelin A Dell et al. , 1995 
Recombinant human protein C Yan et al. , 1993 
Snake venom serine protease (batroxobin) Lochnit and Geyer, 1995 
Honeybee venom phospholipase A2 Kubelka et al. , 1993 
Honeybee venom hyaluronidase Kubelka et al. , 1995 
Schistosomal glycoproteins Srivatsan et al. , 1992 
Dirofilaria immitis (dog heartworm) Kang et al. , 1993
Matrix metalloproteinase-1 (HT-1080 fibrosarcoma cells) Saarinen et al. , 1999 
Tyv1-3GalNAc?1-4(Fuc?1-3)GlcNAc Trichinella spiralis  (intracellular parasite) Reason et al. , 1994
Gal?1-3GalNAc?1-4GlcNAc Ascaris suum  (pig parasitic nematode) Lochnit et al. , 1997
Gal?1-3GalNAc?1-4GlcNAc Lymnaea stagnalis  (hemocyanin) van Kuik et al. , 1987 
Table 1. Occurrence of GalNAcβ1-4GlcNAc-containing glycans
GalNAcT for the oligosaccharide
acceptor from 1-2 mM to 5-10 µM
(Smith and Baenziger, 1988, 1992). Due
to these differences in K
m
-values, this
enzyme is referred to as PXR/K-specific
β1,4-GalNAcT. The sulphotransferase,
which acts after the GalNAc has been
added to the oligosaccharide chain,
requires only the GalNAcâ1-
4GlcNAcâ1-2Maná acceptor structure
for addition of sulfate to the 4-hydroxyl
of the terminal GalNAc (Skelton et al.,
1991; Xia et al., 2000).
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7Bovine milk glycoproteins are
surprisingly rich in lacdiNAc-containing
complex-type glycans (see Table 1 for
references). β1,4-GalNAcT activity has
been identified and characterized in
lactating bovine mammary gland
membranes (van den Nieuwenhof et al.,
1999). This enzyme uses acceptor
substrates carrying terminal GlcNAc in
â-configuration and even free GlcNAc
(van den Nieuwenhof et al., 1999),
differing from the bovine pituitary gland
â1,4-GalNAcT activity by being
independent of a specific peptide motif in
the underlying protein (Smith and
Baenziger, 1992). β1,4-GalT activity,
which is also present in the bovine
mammary gland, relates very
promiscuously to donor substrates, thus
being able to use UDP-GalNAc instead
of UDP-Gal (Palcic and Hindsgaul,
1991). However, â1,4-GalNAcT activity
seems not to be due to the flexible
behavior of â1,4-GalT activity, as
demonstrated by competition
experiments between these two enzymes
and by studying responsiveness against
an inhibiting antibody raised against
bovine â1,4-GalT (van den Nieuwenhof
et al., 1999). Furthermore, in the
presence of á-lactalbumin, a modifier
protein present in lactating mammary
gland directing the β1,4-GalT to
synthesize lactose (Galβ1-4Glc) instead
of lacNAc (Galβ1-4GlcNAc) (Brew et
al., 1968; Schanbacher and Ebner, 1970),
the â1,4-GalNAcT acts on Glc to form
GalNAcâ1-4Glc (van den Nieuwenhof et
al., 1999). This observation also
distinguishes â1,4-GalNAcT from â1,4-
GalT; the latter enzyme is incapable of
transferring GalNAc to Glc despite the
presence of á-lactalbumin (Do et al.,
1995).
However, regardless of the presence
of terminal lacdiNAc determinant on
human glycans, the enzyme responsible
for the synthesis of this structure was not
cloned until 2003. Takashi Sato et al.
(2003) cloned a novel human â1,4-
GalNAcT that catalyzes the formation of
lacdiNAc structure, and the transcript of
the enzyme was shown to be highly
expressed in the stomach, colon, and
testis by quantitative real-time PCR (Sato
et al., 2003). The truncated form of the
enzyme was expressed in HEK293T
cells, and it showed catalytic activity
towards GlcNAc in â-configuration in
vitro, forming GalNAcâ1-4GlcNAc both
with N- and O-glycan-derived acceptor
glycans. An experiment with asialo/
agalacto fetal calf fetuin as an acceptor
glycoprotein, which carries both N- and
O-glycans, implies that the cloned
â1,4GalNAcT recognizes both of these
glycans (Sato et al., 2003).
A peptide motif-independent â1,4-
GalNAcT activity has been also
described in schistosomes (Neeleman et
al., 1994; Srivatsan et al., 1994), snails
(Mulder et al., 1995; Neeleman and van
den Eijnden, 1996), Lepidopteran insect
cells (van Die et al., 1996), human 293
kidney cells (Do et al., 1997), and
nematode C. elegans (Do et al., 1997;
Kawar et al., 2002).
1.2.3. Terminal decoration of the
GalNAcâ1-4GlcNAc unit in vitro
Enzymatic in vitro synthesis of the
terminally decorated lacdiNAc
oligosaccharides has offered the
possibility to study the biosynthesis of
these structures. The terminal sulfation of
lacdiNAc determinant in vitro has been
carried out using bovine pituitary
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8membrane extracts to sulfate the
chemically synthesized trisaccharide
GalNAcâ1-4GlcNAcâ1-2Man (Skelton
et al., 1991; Dharmesh et al., 1993).
Different kinds of acceptor saccharides
containing the lacdiNAc determinant
have been fucosylated in vitro by, for
example, using human milk á3/4-
fucosyltransferase (Bergwerff et al.,
1993), recombinant human
fucosyltransferase V (Pykäri et al., 2000),
recombinant human fucosyltransferase
IV (Study II), and recombinant human
fucosyltransferase VI (Nyame et al.,
1999). Partially purified bovine
colostrum á2,6-sialyltransferase
(Nemansky and van den Eijnden, 1992)
and á2,6-sialyltransferase from different
bovine tissues expressed in COS-7 cells
(Mercier et al., 1999) could catalyze the
in vitro synthesis of terminal NeuNAcá2-
6GalNAcâ1-4GlcNAc.
1.2.4. Biological significance of
lacdiNAc-based oligosaccharide
chains
As a result of intensive research during
the 1990s, numerous glycoconjugates
carrying lacdiNAc-based oligosaccharide
chains have been reported (for
references, see Table 1). Despite the wide
variety of structures encountered, their
biological significance remains obscure.
The functions of these unique structures
are difficult to study due to their presence
in negligible amounts in biological
materials, but as the sensitivity of the
research methods develops, more
functions will be revealed. The proposed
biological functions of pituitary
hormones and glycodelin A are presented
here as examples.
1.2.4.1. Pituitary hormones
The hormones lutropin (LH), follitropin
(FSH), thyrotropin (TSH), and chorionic
gonadotropin (CG) are a family of
closely related glycoproteins. Each
hormone is a dimer consisting of a
common α-subunit and a hormone-
specific â-subunit (Pierce and Parsons,
1981). Lutropin from three different
animal species bears N-linked
oligosaccharides terminating with SO
4
-
4GalNAcâ1-4GlcNAcâ1-2Maná (Green
et al., 1985; Green and Baenziger, 1988a,
1988b). Native bovine lutropin (SO
4
-
4GalNAcâ1-4GlcNAcâ1-2Maná) and
desulfated lutropin (GalNAcâ1-
4GlcNAcâ1-2Maná) were studied for
their capability to bind to the lutropin/
chorionic gonadotropin receptor and to
produce cAMP and progesterone. No
differences in cAMP and progesterone
production were present between these
two glycoforms of the same protein,
indicating that the interaction of
glycoprotein hormones with the lutropin/
chorionic gonadotrophin receptor is not
modulated by sulfation of bovine lutropin
oligosaccharides (Baenziger et al., 1992).
Recombinant bovine lutropin
produced in Chinese hamster ovary
(CHO) cells carrying N-linked
oligosaccharides with terminal structures
NeuNAcá2-3Galâ1-4GlcNAcâ1-2Man
and native bovine lutropin had a
surprisingly large difference in their
metabolic clearance rates, at 1.7%/min
and 7.3%/min, respectively. This implies
that the presence of sulfated rather than
sialylated oligosaccharides on bovine
lutropin is responsible for a shorter
circulatory half-life, having a significant
impact on in vivo bioactivity of this
hormone (Baenziger et al., 1992). A
receptor present on hepatic
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9reticuloendothelial and Kupffer cells is
specific for SO
4
-4GalNAcâ1-
4GlcNAcâ1-2Man structure (Fiete et al.,
1991). It binds to lutropin with an
apparent K
d
 of 1.63 x 10-7M, and the
bound ligand is rapidly internalized,
transported to lysosomes, and degraded,
resulting in a rapid clearance of lutropin
from circulation (Fiete et al., 1991). For
example, the regulation of the circulatory
half-life of lutropin by this receptor is
critical for embryo implantation in vivo
(Mi et al., 2002). The rat liver SO
4
-
4GalNAcâ1-4GlcNAcâ1-2Man-specific
receptor is closely related both
antigenically and structurally to the
macrophage mannose receptor isolated
from the rat lung, but they differ in their
ability to bind ligands bearing terminal
SO
4
-4GalNAc or Man (Fiete and
Baenziger, 1997). The cDNA isolated
from mouse lung encodes the
macrophage/endothelial cell mannose
receptor that binds SO
4
-4GalNAcâ1-
4GlcNAcâ1-2Man- or Man-terminating
oligosaccharides at independent sites
(Fiete et al., 1997). The cysteine-rich
domain at the N-terminus of this receptor
binds to oligosaccharides with terminal
SO
4
-4GalNAc, while calcium-dependent
carbohydrate recognition domains (CRD)
account for binding of Man-terminating
ligands (Fiete et al., 1998; Roseman and
Baenziger, 2000).
1.2.4.2. Glycodelin A
Glycodelin is a major glycoprotein that is
synthesized in the endometrium in
response to the hormones progesterone
and relaxin. In addition to the
endometrium, glycodelin is synthesized
in the fallopian tube, bone marrow,
breast, seminal vesicles, and various
glands in the body, and these isoforms are
differentially glycosylated depending on
the tissue from which they are derived
(reviewed in Seppälä et al., 2001).
Glycodelin A, the amniotic fluid isoform
has three consensus sites for N-
glycosylation (Asn28, Asn63, Asn85)
(Julkunen et al., 1988), the first two of
which are glycosylated (Dell et al.,
1995). The major nonreducing epitopes
in the complex-type glycans are Galâ1-
4GlcNAc (lacNAc), GalNAcâ1-
4GlcNAc (lacdiNAc), NeuNAcá2-
6Galâ1-4GlcNAc (sialylated lacNAc),
NeuNAcá2-6GalNAcâ1-4GlcNAc
(sialylated lacdiNAc), Galâ1-4(Fucá1-
3)GlcNAc (Lewis x), and GalNAcâ1-
4(Fucá1-3)GlcNAc (fucosylated
lacdiNAc) (Dell et al., 1995). Glycodelin
A has been shown in the hemizona assay
to inhibit the binding of human sperm to
the zona pellucida, the binding which is
essential for fertilization (Oehninger et
al., 1995). This binding is proposed to
require a selectin-like interaction
between human sperm and the zona
pellucida (Patankar et al., 1993). A
recombinant form of the human protein
C expressed in human kidney 293 cells
carries biantennary N-linked
oligosaccharides terminating with a
GalNAcâ1-4(Fucá1-3)GlcNAc sequence
(Yan et al., 1993). This sequence is a
potent inhibitor of E-selectin-mediated
adhesion (Grinnell et al., 1994), a
prerequisite binding for anti-
inflammatory properties of this anti-
coagulant factor. By blocking the
selectin-mediated adhesion event by this
same carbohydrate epitope, glycodelin A
performs as a contraceptive. Human
kidney 293 cells can be used to produce
recombinant glycodelin, which carries
the same type of glycan structures as
contraceptive glycodelin A (van den
Nieuwenhof et al., 2000), thus providing
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a means of developing a naturally
occurring contraceptive agent.
In addition to the contraceptive
activities of glycodelin A, it is known to
have immunosuppressive properties
(Pockley et al., 1988; Pockley and
Bolton, 1989, 1990; Okamoto et al.,
1991). These properties have been
proposed to be mediated by the
recognition of α2,6-sialylated lacdiNAc
termini on glycodelin A by CD22, a B
cell-associated receptor (Dell et al.,
1995).
1.3. Glycosyltransferases
Glycosyltransferases that act by adding
monosaccharides one at a time from
high-energy donors to specific positions
on the acceptor saccharide are dealt with
in this section. Transferases involved in
the synthesis of dolicol-linked
oligosaccharide precursor in N-glycan
biosynthesis, those involved in initiation
NH2
Cytoplasm Cytoplasmic 
tail
COOH
Golgi lumen 
Catalytic  
domain
Stem region 
Signal-anchor domain
N-glycans 
Figure 4. General structure of Golgi glycosyltransferases.
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of O-linked glycosylation by adding
monosaccharides to either serine or
threonine, and those involved at the
beginning of glycolipid biosynthesis by
utilizing ceramide as an acceptor
molecule are not considered here.
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glycosyltransferases are located in dis-
tinct but overlapping areas in the Golgi,
forming concentration gradients across
the stack. This subcompartmentalization
of glycosyltransferases is consistent with
their mode of action in protein
glycosylation. Glycosyltransferases act
sequentially such that the oligosaccharide
product of one enzyme functions as the
acceptor saccharide for another enzyme.
There has been a lively debate concerning
the mechanisms by which the
glycosyltransferases are segregated from
the secretory traffic and retained in ap-
propriate subcompartments of the Golgi
apparatus. The lack of sequence homol-
ogy among glycosyltransferases suggests
the absence of a common Golgi retention
signal.
The following two mechanisms have
been proposed to explain how resident
Golgi glycosyltransferases are retained in
this organelle and how they are organized
within Golgi membranes: a) the lipid bi-
layer thickness model (Bretscher and
Munro, 1993; Masibay et al., 1993) and
b) the oligomerization or kin recognition
hypothesis (Machamer, 1991; Nilsson et
al., 1993). The first mechanism is based
on the theory that the retention of the en-
zyme depends on the length of the trans-
membrane domain of the protein and the
thickness of the membrane in the Golgi
complex. A shorter transmembrane do-
main prevents the Golgi proteins from
entering cholesterol-rich transport
vesicles, thus resulting in Golgi retention.
This hypothesis was supported by the
observation that increasing the length of
the ST6Gal I transmembrane domain
from 17 amino acids to 23 leucines re-
sulted in the localization of the enzyme
into the plasma membrane (Munro,
1991). On the other hand, proteins tar-
geted to the plasma membrane were accu-
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1.3.1. General features of
glycosyltransferases
1.3.1.1. Structure
Glycosyltransferases are enzymes func-
tioning in the biosynthesis of oligo- and
polysaccharides, which are attached to
proteins, lipids, or proteoglycans. All
Golgi glycosyltransferases are type II
transmembrane proteins. They consist of
a short amino-terminal cytoplasmic do-
main, a transmembrane domain, and a
stem region followed by a carboxy-termi-
nal catalytic domain facing the lumen of
the Golgi apparatus (Fig. 4).
Glycosyltransferases themselves are of-
ten posttranslationally modified by
glycosylation, especially by N-
glycosylation. Although these enzymes
share a common topology, sequence simi-
larity between glycosyltransferases be-
longing to different families is rare. In-
stead, glycosyltransferases within func-
tionally related families share amino acid
sequences. For example, the members of
the human α1,3-fucosyltransferase fam-
ily (FucT-III, FucT-V, FucT-VI) share
85% of amino acids in their primary se-
quences (reviewed in Niemelä, 1999).
Soluble forms of the glycosyltransferases
are present in biological fluids, and they
are formed via proteolytic cleavage,
which occurs at the stem region of the
transferase.
1.3.1.2. Subcellular localization
Proteins destined for the secretory path-
way travel from the endoplasmic reticu-
lum (ER) to the plasma membrane via the
Golgi apparatus. Protein glycosylation
begins in the ER and continues in the
Golgi apparatus while the proteins move
along the secretory pathway. The
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mulated in the Golgi apparatus when their
transmembrane domains were shortened
from 23 amino acids to 17 residues
(Munro, 1995). The second mechanism
relies on the assumption that the
glycosyltransferases are induced to form
insoluble homo- or hetero-oligomers
when they arrive at the correct Golgi
compartment. These large protein aggre-
gates are excluded from the transport
vesicles destined for later secretory com-
partments. Two medial-Golgi enzymes,
GlcNAcT I and Mann II (mannosidase
II), were relocated into the ER when ei-
ther one was supplied with an ER reten-
tion signal, implying an interaction be-
tween these two enzymes (Nilsson et al.,
1994). The trans-Golgi enzyme GalT I, by
contrast, was not retained by either ER-
retained medial-Golgi transferase
(Nilsson et al., 1994), further supporting
the idea that the enzymes are
oligomerized. But neither the bilayer
thickness model nor the oligomerization
or kin recognition hypothesis alone ex-
plains the localization of
glycosyltransferases in the Golgi com-
plex. Opat et al. (2001) have suggested
yet another model for the localization of
medial- and late-Golgi resident trans-
ferases. This model is based on the dual
transport system across the Golgi stack,
where vesicular transport and cisternal
progression occur simultaneously. In this
model, medial-Golgi enzymes are
thought to form large oligomers that are
excluded from anterograde vesicular
transport. Instead they move by cisternal
progression through the Golgi stack (for
detailed information about anterograde
vesicular transport and cisternal progres-
sion, see Storrie and Nilsson, 2002).
Upon arrival in the trans-Golgi network
(TGN), these large oligomers are packed
into retrograde transport vesicles and re-
turned to the medial-Golgi. By contrast,
late-Golgi enzymes could exploit the an-
terograde vesicular traffic and arrive
quickly at the TGN. The low pH of the
TGN may result in complex formation
between late-Golgi enzymes, which has
been demonstrated for one of the late-
Golgi enzymes, namely ST6Gal I (Chen
et al., 2000). Complex formation restricts
the forward movement of late-Golgi en-
zymes in the secretory pathway.
1.3.1.3. Function
Glycosyltransferases act by adding
monosaccharide units from high-energy
donors to saccharide chains. They
catalyze trans-glycosylation reactions
and are extremely regioselective and
stereo-specific (Ichikawa et al., 1992),
distinguishing between different carbon
atoms in a ring and the α/β-anomericity
of the monosaccharide units. Their
catalytic activity is usually dependent on
divalent cations (the most common ones
being Mg2+ and Mn2+), and their pH
optimum from 5.0 to 7.0 reflects the pH
found in the ER-Golgi pathway. There are
several factors affecting the final
structure of the glycans on a certain
glycoconjugate traveling through the
Golgi. These factors include the
expression of certain glycosyl-
transferases in a given time and cell type.
The availability of nucleotide sugar
donors in the Golgi lumen is also
essential. The donors are synthesized in
the cytoplasm (or in the nucleus in the
case of CMP-sialic acid), after which
they are transported across the Golgi
membrane by specific nucleotide sugar
transporters (reviewed in Gerardy-
Schahn et al., 2001) to the lumen, where
the catalytic ectodomains of the
glycosyltransferases are located. In
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addition to the availability of nucleotide
sugar donors, the concentration of the
acceptors in the lumen of the Golgi
influences the glycosylation of a given
glycoconjugate. The presence of
nucleotide sugars, or oligosaccharide-
hydrolyzing enzymes, combined with the
competition between glycosyltrans-
ferases for the same substrate molecules
also affect the final structures of glycans
being synthesized.
1.3.2. Need for expression of
recombinant glycosyltransferases
Glycans expressed on cell surfaces
perform many biologically important
functions. They are involved in adhesion
and recognition events, including
selectin-mediated cell adhesion, host-
pathogen recognition, and carbohydrate-
mediated immune recognition.
Prevention of these binding events is
desirable in, for example, acute xenograft
rejection and pathogen invasion. This
could be accomplished by soluble
oligosaccharides, which compete for
binding to natural ligands, thus inhibiting
the first critical steps of adhesion or
recognition. The biological activities are
mostly carried out by the complex end
structures of glycans, which protrude
from cell surfaces to be recognized by
their counter receptors. Examples of
these terminal epitopes are presented in
Figure 3. Oligosaccharides to be used as
binding inhibitors are difficult, if not
impossible, to purify in sufficient
quantities from tissues or cell cultures.
Nevertheless, these oligosaccharides can
be synthesized in vitro either chemically,
enzymatically, or chemo-enzymatically
(Ichikawa et al., 1992). So far, the
chemical synthesis of complex
oligosaccharide structures lies beyond
any reasonable cost-benefit ratio, so
enzymatic and chemo-enzymatic
syntheses are the methods of choice. In
vivo, these terminal glycan structures are
assembled on the common core
structures present on N- and O-glycans
and glycolipids, and their formation is
catalyzed by specific glycosyltrans-
ferases located in the Golgi apparatus as
described above. The glycosyltrans-
ferases are very difficult to obtain from
tissue extracts or biological fluids using
traditional biochemical methods because
of their presence in scarce amounts and
the presence of other disturbing
enzymatic activities.
In 1989 John B. Lowe and his co-
workers (Larsen et al., 1989) introduced
expression cloning to the field of
glycobiology. This technique enables
cloning of a cDNA that encodes a
glycosyltransferase without the need to
purify the enzyme protein. Because most
glycosyltransferases are glycosylated
themselves, they have to be correctly
glycosylated and properly folded to be
biologically active. All of these
posttranslational modifications take
place in the organelles of the secretory
pathway in eukaryotic cells while the
proteins are moving from the site of
translation to their final destinations
through the ER-Golgi pathway. The
expression system to be used, whether it
is mammalian, eukaryotic, or
prokaryotic, must be carefully evaluated
as a whole. The factors that should be
considered are cell growth
characteristics, expression levels, intra-
and extracellular expression,
posttranslational modifications, and
biological activity of the protein as well
as its intended use.
Introduction
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1.4. Production of recombinant proteins in yeasts
simple to cultivate on inexpensive growth
media, and many well-known techniques
are available for genetic and molecular
manipulation of foreign genes. It is one
of the best-characterized eukaryotes, with
its entire genome being sequenced in
1996. The secretory pathway of S.
cerevisiae contains the same cellular
compartments as mammalian cells. Thus,
it has the means to perform
posttranslational modifications and
A.
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Figure 5. N- and O-glycosylation in S. cerevisiae. A. Structure of the core N-glycan attached
to asparagine residues on proteins within the sequence Asn-x-Ser/Thr (x≠Pro). Before the
newly glycosylated protein is transported from the ER to the Golgi, the glycan is trimmed by
glycosidases at sites designated with arrows. B. The Golgi-elongated polymannose type N-
glycan. C. O-glycosylation starts in the yeast ER by the attachment of the first mannose to
Ser/Thr residues on the protein, whereas elongation takes place in the Golgi. Yeast O-glycans
contain 1-5 mannose residues. The symbols on the right indicate the glycosidic linkages cre-
ated between the monosaccharides.
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The yeast Saccharomyces cerevisiae has
been used for almost three decades as a
host organism for the expression of
recombinant proteins of eukaryotic origin
for research, industrial, and medical
purposes (reviewed in Romanos et al.,
1992). S. cerevisiae has also been used
for thousands of years by mankind in
brewing and baking, and this is why it has
been granted the GRAS (generally
recognized as safe) status. It is easy and
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secretion, resulting in protein products
that are, if not identical, more similar to
the native protein than those expressed in
prokaryotic cells.
Glycosylation is the most common
and the most complex form of
posttranslational modification. It affects
the final structure of the glycosylated
protein, and thus, its biological activity in
vivo, and the majority of therapeutic
recombinant proteins are glycosylated in
their native form. Yeasts are capable of
performing both O- and N-glycosylation
of secretory proteins. The N-
glycosylation begins with the transfer of
a preformed oligosaccharide core from
dolicyl pyrophosphate to the amide group
of asparagine within the tripeptide, Asn-
X-Thr(Ser), where X may be any amino
acid except proline. However, the N-
glycans on glycoproteins produced by S.
cerevisiae consist primarily of mannose
residues, and the average mannose chain
length can be as large as 50-100 units.
The O-glycans consist solely of mannose
chains attached to serine or threonine
residues (Fig. 5) (Herscovics and Orlean,
1993).
Hyperglycosylation reduces the
benefits of S. cerevisiae as an expression
system. Many yeasts, such as
methylotrophic Pichia pastoris and
Hansenula polymorpha, tend not to
glycosylate proteins to this extent (Faber
et al., 1995; Bretthauer and Castellino,
1999; Gellissen, 2000; Lin Cereghino
and Cregg, 2000), although the glycans
are also composed of mannose. High-
mannose-type glycans are recognized by
mannose receptors on mammalian cells,
and the glycoproteins are removed from
the circulation by endocytosis. In
addition, high-mannose-type glycans are
immunogenic. This dramatically reduces
the effect of heterologous therapeutic
proteins produced in yeast. As a
consequence, extensive work has been
carried out to produce secretory
glycoproteins devoid of high-mannose-
type glycans in yeast (Melnick et al.,
1990; Yip et al., 1994; Lehle et al., 1995).
An ambitious cell engineering project
aimed at constructing the complete
mammalian-type glycosylation system in
S. cerevisiae using glycosylation mutants
(Äoch1, Ämnn1, Ämnn4), which are
unable to polymannosylate the glycans
(Chiba et al., 1998; Malissard et al.,
1999). The N-glycosylation pathways of
mammalian cells and yeast cells diverge
in the Golgi apparatus (Herscovics and
Orlean, 1993). The á1,2-mannosidase
from Aspergillus satoi was successfully
expressed in the yeast ER. This enzyme
converted the Man
8
GlcNAc
2
 structure
produced by the glycosylation mutants
into Man
5
GlcNAc
2
 structure (Chiba et
al., 1998), which is the intermediate form
for mammalian hybrid- and complex-
type sugar chains. But to achieve
elongation and termination of complex
mammalian glycans, additional enzymes
and nucleotide sugar transporters must be
introduced into yeast. Mammalian cells
therefore remain the primary expression
system for generating glycosylated
therapeutic recombinant proteins (Eckart
and Bussineau, 1996; Grabenhorst et al.,
1999).
1.4.1. Saccharomyces cerevisiae
Efficient expression of recombinant
protein in yeast requires the use of
expression vectors that contain a
promoter and terminator, selection
marker, and DNA sequences encoding
for a signal peptide and polypeptide
carrier.
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1.4.1.1. Expression vectors
Yeast expression vectors work as shuttle
vectors, i.e. they possess bacterial
sequences which aid in the vectors being
selected and propagated in E. coli
(Romanos et al., 1992; Malissard et al.,
1999). Both integrative and episomally
replicating plasmids are used to
transform yeast cells. Episomal
autonomously replicating plasmids can
be divided into two subgroups: YEp and
YCp. The YEp plasmids use the
partitioning system of the endogenous
yeast plasmid known as 2µ circle, giving
rise to a high copy number (10-40 copies
per cell). Characteristic to YCp is the
chromosomal centromere, which
connects the plasmid with the mitotic
spindle apparatus. As a result, the
plasmid copy number is limited (1-2
copies per cell) (Malissard et al., 1999).
Expression of episomal plasmids
requires continuous selection on a
minimal growth medium, resulting in
lower cell densities than in a rich
medium. Chromosomal integration of
integrating vectors (YIp) offers a more
stable alternative to episomal
maintenance of foreign DNA (Romanos
et al., 1992). YIp vectors integrate
normally by homologous recombination,
and they contain yeast chromosomal
DNA to target integration, the selectable
marker, and the bacterial replicon
(Romanos et al., 1992). After the desired
DNA sequence has been integrated into
the yeast chromosome, the cells can be
grown on a rich medium to much higher
cell densities than in a minimal medium
without risking the loss of the desired
gene (Malissard et al., 1999).
1.4.1.2. Promoters
Efficient transcription of foreign genes in
yeast is dependent on promoters of yeast
origin (Hitzeman et al., 1981). Both
regulated and constitutively active
promoters are used. The advantage of the
use of the former is that the growth stage
can be separated from the expression
stage; production of proteins toxic to the
host organism, for intance, requires the
use of a regulated promoter. The cells can
thus be grown to high cell densities
before they begin to express the toxic
protein. The use of poorly regulated
promoters is unsuitable in large-scale
cultures, in which the risk for selection of
nonexpressing cells is high. Glycolytic
promoters (ADH1, PGK, GAP) are the
most powerful ones of S. cerevisiae, but
they are poorly regulated (Romanos et
al., 1992; Malissard et al., 1999).
Galactose-regulated promoters (GAL1,
GAL7, GAL10) are the most powerful
tightly regulated promoters of S.
cerevisiae. They are strongly repressed by
glucose, but many strains have mutations
in the galactose permease gene (GAL2),
and thus, are not inducible by galactose
(Romanos et al., 1992). Another class of
regulated promoters is glucose-
repressible promoters of ADH2, SUC2,
and CYC1 genes, which encode alcohol
dehydrogenase II, invertase, and iso-1-
cytochrome c, respectively (Romanos et
al., 1992; Malissard et al., 1999). Genes
involved in galactose or sucrose
metabolism are repressed by glucose
because yeasts prefer glucose that
directly enters the glycolytic pathway. In
addition to these metabolically expressed
promoters, inorganic salts can be used to
activate certain promoters. These include
the promoter of acid phosphatase gene
(PHO5), which is regulated by inorganic
Introduction
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phosphate, and the promoter of copper
metallothionein (CUP1), which is tightly
regulated by Cu2+ ions (Romanos et al.,
1992).
Yet another class of yeast promoters is
of interest because the induction is
independent of culture conditions. They
can be regulated without interfering with
the culture just by shifting the cells to a
higher growth temperature. A gene
encoding secretory heat shock protein
hsp150 is regulated by heat shock and
nitrogen starvation. Shifting the cells
from their physiological temperature of
24°C to 37°C increases the steady-state
level of the HSP150 mRNA and the
amount of synthesized hsp150 protein
(Russo et al., 1992, 1993). This promoter
has been used to induce the expression of
several heterologous proteins in S.
cerevisiae (Simonen et al., 1994, 1996;
Mattila et al., 1996).
1.4.1.3. Terminators
Yeast transcription terminators are
needed for the proper formation of
mRNA 3’ ends and for obtaining
maximal expression levels. Often the
yeast terminator corresponding to the
promoter is used just to simplify the
vector construction, and for the same
reason, a terminator from the 2µ circle
(either FLP or D gene terminator) can be
exploited (Romanos et al., 1992;
Malissard et al., 1999).
1.4.1.4. Selectable markers
The yeast transformants must be
screened for successful transformation.
This is done with the aid of selectable
markers, either auxotrophic or dominant,
introduced into the cloning vectors. The
most commonly used markers for
selection of yeast transformants are
LEU2, TRP1, URA3, and HIS3. Thus,
mutant strains, auxotrophic for leucine,
tryptophane, uracil, and histidine, are
used. Dominant selectable markers
usually encode resistance to some
antibiotic. Antibiotic resistance markers,
commonly used in yeast transformation,
include aminoglycoside G418 resistance
marker, hygromycin B resistance marker,
and chloramphenicol resistance marker
(Romanos et al., 1992).
1.4.1.5. Signal peptides
S. cerevisiae secretes only about 0.5% of
its own proteins. Thus, the secreted
heterologous protein is easy to purify
from the growth medium, and this
eliminates the need for costly and low-
yielding cell-disruption and refolding
steps. Although intracellular expression
of proteins requires extra purification
steps, it is the system of choice for
heterologous proteins that are normally
expressed in the cytoplasm (Eckart and
Bussineau, 1996). As in higher
eukaryotes, targeting of proteins to the
secretory pathway is directed by an N-
terminal signal peptide required for
translocation of the protein into the ER
lumen (Blobel and Dobberstein, 1975). A
classical signal peptide is composed of a
charged N-terminus, followed by a
hydrophobic core and a consensus
sequence for cleavage in the ER by signal
peptidase. Despite signal peptides being
recognized with low specificity in yeast,
foreign signal peptides do not usually
work (Romanos et al., 1992). Therefore,
the most widely used signal peptides are
of yeast origin, like those of acid
phosphatase, invertase, and mating factor
á (Brake et al., 1984; Malissard et al.,
1999).
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1.4.1.6. Carrier polypeptides
Once in the ER, a default pathway is
thought to direct a protein either to the
plasma membrane, unless it contains a
specific signal that retains it in the ER or
Golgi, or to the vacuole. However, there
are many stages along the yeast secretory
pathway where the journey of the protein
being secreted may be hampered, and
usually heterologous proteins are incor-
rectly folded and fail to be secreted
(Romanos et al., 1992). Many of the re-
tained proteins can be rescued by fusing
them to a carrier polypeptide, which helps
them to achieve their proper conforma-
tion and guides them out of the ER and
through the secretory pathway. The most
commonly used carrier polypeptide is the
prepro-fragment (amino acids 1-83) of
the S. cerevisiae α-factor precursor
(Brake et al., 1984; Singh et al., 1984;
Brake, 1990). α-Factor, a 13-amino acid
mating pheromone required for mating, is
secreted by S. cerevisiae α-cells (Thorner,
1981). The pheromone molecules are ini-
tially synthesized as larger precursor
polypeptides, which are then processed to
yield the mature species (Fig. 6) (Julius et
al., 1983). The proposed prepro-α-factor
precursor (165 amino acids in total) of S.
cerevisiae consists of a 19-amino acid
hydrophobic signal peptide, an additional
leader region of 66 amino acids, and four
identical repeats of the mature 13-amino
acid pheromone separated by similar
spacer peptides (6-8 residues) (Kurjan
and Herskowitz, 1982; Brake et al.,
1983). Processing of prepro-α-factor pre-
cursor requires four different proteolytic
activities (Fig. 6). Signal peptidase
cleaves between amino acids 19 and 20,
releasing the signal peptide (pre) in the
ER (Waters et al., 1988). The resulting
pro-α-factor is cleaved by Kex2
endoproteinase, which cleaves on the car-
boxyl side of the Lys-Arg sequence in the
spacer peptide of each repeat (Leibowitz
and Wickner, 1976; Julius et al., 1984).
Kex1 carboxypeptidase removes the
arginyl and lysyl residues at the C-termi-
nus of each of the first three repeats
(Dmochowska et al., 1987). Finally, be-
fore the mature pheromone is released to
the extracellular environment, the mem-
brane-bound dipeptidylaminopeptidase
Figure 6. Structure and processing of the prepro-α-factor. For detailed explanation of the
processing steps, see Section 1.4.1.6.
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Ste13 removes the Glu-Ala and Asp-Ala
dipeptides from the N-terminus of each
repeat (Julius et al., 1983). The prepro-
region of the mating factor α-precursor
contains enough information to target the
heterologous proteins fused to its C-ter-
minus for processing and secretion in S.
cerevisiae (Brake et al., 1984; Brake,
1990).
Another carrier polypeptide is derived
from the secretory heat shock protein
Hsp150 of S. cerevisiae, which has been
cloned and characterized in our labora-
tory (Fig. 8A) (Russo et al., 1992).
Hsp150 is constitutively expressed, highly
O-glycosylated, and secreted efficiently
to the culture medium (Russo et al.,
1992). Indeed, it is one of the few proteins
secreted to the culture medium of S.
cerevisiae (Tanner and Lehle, 1987).
HSP150 gene expression is regulated by
heat shock and nitrogen starvation (Russo
et al., 1993). The primary translation
product of HSP150 gene (413 amino ac-
ids) consists of an 18-amino acid signal
peptide, followed by subunits I (amino
acids 19-72) and II (amino acids 73-413).
Subunit II is divided into 11 tandem re-
peats of 19 amino acids (amino acids 73-
299) and C-terminal amino acids (300-
413) (Russo et al., 1992). The signal pep-
tide is cleaved off in the ER by signal
peptidase, and Kex2p in the Golgi appa-
ratus removes subunit I, yielding peptide
fragments of 53 and 341 amino acids
(Russo et al., 1992). The Hsp150∆ carrier
is an N-terminal fragment of the authen-
tic Hsp150 secretory protein containing
the first 321 amino acids (see Fig. 8D and
8H) (Simonen et al., 1994, 1996; Jämsä
et al., 1995). The Hsp150∆ carrier pro-
motes proper folding in the yeast ER of
heterologous proteins fused to its C-ter-
minus, which results in efficient secretion
of the fusion proteins (Simonen et al.,
1994, 1996; Jämsä et al., 1995; Mattila et
al., 1996).
1.4.2. Pichia pastoris
Despite the successes of S. cerevisiae as
a host organism for the expression of
recombinant proteins, low yields often
limit its use. Methylotrophic yeasts, such
as Pichia pastoris, provide much higher
yields than S. cerevisiae. Moreover, they
do not extend the N-glycans, as
encountered with S. cerevisiae (Faber et
al., 1995; Gellissen, 2000; Lin Cereghino
and Cregg, 2000). The increasing
popularity of the P. pastoris expression
system arises from the simplicity and
similarity of the techniques to those of S.
cerevisiae, as well as from the ability of
P. pastoris to produce foreign proteins at
high levels either intra- or extracellularly.
The capability of P. pastoris to carry out
posttranslational modifications and the
commercial availability of the expression
system as a kit also make it an attractive
choice as a host organism (Lin Cereghino
and Cregg, 2000). The heterologous gene
expression in P. pastoris is based on a
strong and regulatable promoter derived
from genes of the methanol utilization
pathway (Gellissen, 2000). When grown
on methanol, this yeast produces 30% of
total soluble protein as an alcohol oxidase
(Ellis et al., 1985; Cregg et al., 1993),
one of the key components of the
methanol utilization pathway. The initial
reactions of this pathway (Fig. 7) (Egli et
al., 1980; Gleeson and Sudbery, 1988;
Gellissen, 2000; Lin Cereghino and
Cregg, 2000) take place in specialized
organelles, peroxisomes, with subsequent
steps occurring in the cytoplasm.
In peroxisomes, methanol is oxidized
to formaldehyde (HCHO) and hydrogen
peroxide (H
2
O
2
). P. pastoris has two
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alcohol oxidase genes, AOX1 and AOX2.
Studies of strains with disrupted AOX
genes have revealed that Aox1p is the
dominant alcohol oxidase and that its
expression is controlled at the
transcription level (Cregg et al., 1989).
Regulation of the AOX1 gene involves a
repression/derepression mechanism and
an induction mechanism. The repression/
derepression mechanism is based on the
presence and then absence of a repressing
carbon source, such as glucose or
CH3OH
DHA  DHAP 
FBP       F6P
GAP
Peroxisome 
CH3OH
HCHO 
GAP DHA
HCHO 
H2O2
O2
Cytosol 
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NAD NADH 
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NAD NADH 
1/3GAP 
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Figure 7. Methanol utilization pathway and its compartmentalization in Pichia pastoris.
Methanol (CH
3
OH) is oxidized by alcohol oxidase (1) within the peroxisome to produce form-
aldehyde (HCHO) and hydrogen peroxidase (H
2
O
2
). Hydrogen peroxidase is reduced to wa-
ter (H
2
O) and molecular oxygen (O
2
) by catalase (2). Formaldehyde may diffuse to the cyto-
sol, where it spontaneously reacts with reduced glutathione (GS). This complex is subsequently
oxidized to formate (HCOOH) and then carbon dioxide (CO
2
) by the actions of formaldehyde
dehydrogenase (3) and formate dehydrogenase (4), respectively. Alternatively, formaldehyde
may react with xylulose 5-phosphate (Xu
5
P) by the action of dihydroxyacetone synthase (5)
within the peroxisome to produce glyceraldehyde 3-phosphate (GAP) and dihydroxyacetone
(DHA). Phosphorylation of DHA to dihydroxyacetone phosphate (DHAP) by the action of
dihydroxyacetone kinase (6) in the cytosol facilitates the production of fructose 1,6-
bisphosphate (FBP) by fructose 1,6-bisphosphate aldolase (7) and its dephosphorylation to
fructose 6-phosphate by fructose 1,6-bisphosphatase (8). Subsequent rearrangement reactions
generate Xu
5
P, which is recycled to react with formaldehyde. The net product of this path-
way is generation of one-third of the GAP molecules for biomass (adapted from Gleeson and
Sudbery, 1988).
glycerol, but the presence of methanol is
essential for high-level production of
Aox1p (Tschopp et al., 1987).
Formaldehyde formed in the oxidization
reaction enters both the cytosolic
dissimilatory pathway to yield energy
and the assimilatory pathway to generate
biomass so P. pastoris can utilize
methanol as its sole carbon source (Egli
et al., 1980; Ellis et al., 1985; Gleeson
and Sudbery, 1988; Lin Cereghino and
Cregg, 2000). In addition, methanol is
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toxic or at least growth-inhibitory to
several other organisms, and thus, it
reduces contamination of P. pastoris
cultures. However, in some cases, the use
of the methanol-inducible AOX1
promoter is not suitable, when, for
example, producing food products or in
large-scale fermentations, where large
quantities of methanol become
dangerous. Alternative promoters are
Pichia pastoris GAP, FLD1, PEX8, and
YPT1 (Liu et al., 1995; Waterham et al.,
1997; Sears et al., 1998; Shen et al.,
1998;).
One disadvantage of P. pastoris as a
host organism is the shortage of
selectable markers. They have been
limited to the biosynthetic pathway genes
HIS4 from P. pastoris or S. cerevisiae,
ARG4 from S. cerevisiae, and Sh ble from
Streptoalloteichus hindustanus, which
codes for resistance to the bleomycin-
related drug zeocin. However, a new set
of biosynthetic markers has been isolated
and characterized (Lin Cereghino et al.,
2001), thus providing more alternatives
for selecting P. pastoris transformants.
P. pastoris has an additional
advantage over S. cerevisiae as a host
organism for production of heterologous
proteins: it is a poor fermenter. When
grown to high cell densities, S. cerevisiae
produces ethanol as the fermentation
product. Ethanol rapidly reaches the toxic
level, which limits further growth and
production of recombinant proteins. P.
pastoris prefers aerobic growth and can
therefore reach extremely high cell
densities (OD
600
 ~ 500). This
phenomenon is particularly important
when the concentration of the secreted
protein is proportional to the
concentration of the cells in the culture
(Lin Cereghino et al., 2002).
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2  AIMS OF THE STUDY
I To evaluate the acceptor specificity of â1,6-N-acetylglucosaminyltransferase
derived from human PA1 cells.
II To explore the capability of mammalian glycosyltransferases to catalyze the
formation of polylactosaminoglycans containing an internal lacdiNAc unit.
III To determine the acceptor and substrate specificities of glycosyltransferases
and glycosidases, respectively, with lacdiNAc-containing saccharides.
IV To compare the folding and secretion of the catalytic ectodomain of rat á2,3-
sialyltransferase fused to the Hsp150Ä and MFá carriers in the yeasts
Saccharomyces cerevisiae and Pichia pastoris, and to compare the strength of
the HSP150 promoter with that of the GAL1, ADH1, and PGK1 promoters.
V To express rat á2,3-sialyltransferase and human á1,3-fucosyltransferase VII in
Saccharomyces cerevisiae and Pichia pastoris, and to use the recombinant yeast
strains in the synthesis of sLex antigen, a determinant of selectin ligands.
Aims of the Study
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3. MATERIALS AND METHODS
Experimental methods used in this study are listed in Table 2. Detailed descriptions
of the methods are given in the original publications or references therein. The
glycosyltransferases and glycosidases used are listed in Tables 3 and 4, respectively,
and the detailed reaction conditions are described in the original publications. Table
5 presents all of the acceptor and control glycans used, with detailed information on
their synthesis given in the references. Table 6 lists the applied yeast strains, and a
schematic representation of the carrier and fusion proteins is presented in Figure 8.
Table 2. Methods
Materials and Methods
Method Study
Chromatography
Size exclusion chromatography II
Ion exchange chromatography II-IV
Affinity chromatography I, II
Paper chromatography I
Mass spectrometry and NMR spectroscopy
Positive-ion MALDI-TOF MS I, II
One-dimensional
1
H-NMR spectroscopy I, II
Two-dimensional NMR spectroscopy II
Molecular biology
Bacterial transformation I, III, IV
Baculovirus transfer vector construction/plasmid contruction I, III, IV
Cell wall isolation III, IV
Immunoprecipitation III, IV
Isolation and treatment of cell walls III, IV
?-Lactamase activity assay III
Metabolic labeling III, IV
Northern blotting I
Nucleotide sequencing III, IV
Proteinase K digestion IV
SDS-PAGE I, III, IV
Sf9 insect cell transfection I
Western analysis I, III, IV
Yeast transformation (P. pastoris ) III, IV
Yeast transformation (S. cerevisiae ) III, IV
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A           Hsp150
B           Hsp150TRUNC
C           ST3N
D           Hsp150?-ST3Ne
E           MF? precursor
F           MF?-ST3Ne
G           FucTVII
H           Hsp150?-FucTe (S.c.)
I           Hsp150?-FucTe (P.p.)
J           ?-lactamase
K           Hsp150?-?-lactamase
L           Native IGnT6 
M           GST-IGnT6 
1 18 72 299 413
SP SUI SU II 
1  18       72                                      299 324 
1 8   28                                                                374 
  1 19           85  102  123  144  165  
  spacers 1-4 
α1 α2   α3 α4
1  19          83                                                                    429 
1 14 36                                                           341 
1  23                                                  286 
1  18      72                                        299  321                                                586 
1    26                                                                                         400 
1      38                                                      270                                                                                        645 
1  18       72                                        299 321                                                         617 
1  19        73                                                                                                                  632 
TSGYLEKREAEAEF 
1 18 72 299 321 667
300 322 336 
Figure 8.
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Figure 8. Carrier polypeptides and recombinant proteins used in this study. (A) Hsp150
consists of a signal peptide (SP) and subunits (SU) I and II. SUII is composed of 11 repeats
of homologous 19 amino acid peptides and a unique C-terminal fragment. (B) Truncated
Hsp150 (Hsp150
Trunc
) consists of the 319 N-terminal amino acids of Hsp150, and 5 additional
amino acids (NLINC) in the C-terminus. (C) Rat liver ST3N consists of an N-terminal
cytoplasmic tail of 8 amino acids, a transmembrane domain (amino acids 9-28), and a catalytic
ectodomain of 346 amino acids. (D) ST3Ne joined to the C-terminus of Hsp150Ä carrier. (E)
The mating factor α (MFα) precursor is composed of the 85-amino acid leader sequence and
four 13-amino acid MFα repeats (α1-α4), which are separated from each other by a peptide
spacer of 5-8 amino acids that contains the Kex2p cleavage site. (F) ST3Ne fused to the MFα
carrier without the Kex2p processing site. (G) Human á1,3-fucosyltransferase VII consists
of 14-amino acid N-terminal cytoplasmic tail, a transmembrane domain (amino acids 15-36),
and a catalytic ectodomain of 295 amino acids. (H) Catalytic ectodomain of human α1,3-
fucosyltransferase VII (FucTe) fused to the C-terminus of the Hsp150Ä carrier. (I) FucTe fused
to the Hsp150Ä carrier. The original signal peptide is replaced by the MFα signal peptide.
FucTe and the Hsp150Ä carrier are separated by a Kex2 protease cleavage site. (J) â-lactamase
of E. coli contains a 23-amino acid signal sequence, and the enzyme itself is composed of
263 amino acids. (K) â-lactamase joined to the C-terminus of Hsp150Ä carrier. (L) Native
IGnT6. (M) GST-IGnT6 consists of an N-terminal gp67 signal peptide (amino acids 1-38),
a glutathione-S-transferase (GST) coding region (amino acids 39-270), and the sequence
coding for the stem and the Golgi lumenal regions of native IGnT6.
The numbers indicate the last amino acid of each domain. N-glycosylation sites are designated
with arrows.
Table 3. Glycosyltransferase reactions
Glycosyltransferase Source of enzyme EC number Study
?1,4-Galactosyltransferase Bovine milk, Sigma EC 2.4.1.90 II
?1,3-Galactosyltransferase Colo 205 cell lysate II
?1,4-N-Acetylgalactosaminyltransferase Bovine milk, Sigma EC 2.4.1.90 II
?1,3-N-Acetylglucosaminyltransferase Human serum II
Distally acting ?1,6-N-Acetylglucosaminyltransferase Hog gastric mucosal microsomes II
Centrally acting ?1,6-N-Acetylglucosaminyltransferase (a) Human, produced in S. frugiperda EC 2.4.1.150 I, II
Centrally acting ?1,6-N-Acetylglucosaminyltransferase (b) Rat serum II
?1,3-Fucosyltransferase IV Human, produced in BHK-21 cells EC 2.4.1.152 II
?1,3-Fucosyltransferase VII Human, produced in yeast EC 2.4.1.152 IV
?2,3-Sialyltransferase Rat, produced in yeast EC 2.4.99.5 III, IV
Table 4. Glycosidase reactions
Glycosidase Source of enzyme EC number Study
Endo-?-galactosidase Bacteroides fragilis , Boehringer EC 3.2.1.103 I, II
?-Galactosidase Jack bean, Seikagaku EC 3.2.1.23 I, II
?-N-Acetylhexosaminidase Jack bean, Sigma EC 3.2.1.52 II
?2,3,4,6,-N-Acetylglucosaminidase Streptococcus pneumoniae,  produced in E. coli, Calbiochem EC 3.2.1.30 II
?1,4-Galactosidase (Diplococcus pneumoniae ) Diplococcus pneumoniae,  Boehringer EC 3.2.1.23 II
Materials and Methods
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Table 6. Yeast strains
S. cerevisiae strain Relevant mutation Recombinant protein Study Source/Reference
H1 none III, IV R. Schekman
H23 ∆ hsp150 III, IV Russo et al. , 1992
H335 none (PHSP150 )Hsp150?-?-lactamase III Simonen et al., 1994
H430 ∆ hsp150 Hsp150TRUNC III Fatal et al. , 2002
H626 ∆ hsp150 Hsp150?-ST3Ne III, IV Mattila et al , 1996
H649 ∆ hsp150 Hsp150?-?1,3FucTe IV This study
H970 ∆ hsp150 Hsp150?-ST3Ne, Hsp150?-?1,3FucTe IV This study
H1120 ∆ hsp150 MF?-ST3Ne III This study
H1208 ∆ hsp150 (PPGK1 )Hsp150?-?-lactamase III This study
H1209 ∆ hsp150 (PGAL1 )Hsp150?-?-lactamase III This study
H1210 ∆ hsp150 (PADH1 )Hsp150?-?-lactamase III This study
P. pastoris strain Relevant mutation Recombinant protein Study Source/Reference
P714 none III, IV Invitrogen
P1402 none Hsp150?-ST3Ne III, IV This study
P1403 none MF?-ST3Ne III This study
P1755 none Hsp150?-?1,3FucTVII IV This study
Table 5. Acceptor and control oligosaccharides
Materials and Methods
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Figure 9. (A) Sialyl Lewis x (sLex) tetrasaccharide. (B) and (C) Linear tetravalent sLex glycan
presented in two different ways.
4. RESULTS
4.1. Centrally acting â1,6-N-acetylglucosaminyltransferases
Multiply branched polylactosamino-
glycans with distal lacNAc units
decorated with á2,3-N-acetylneuraminic
acid and á1,3-fucose (sLex) (Fig. 9) have
been shown in in vitro experiments to be
nanomolar L-selectin antagonists
(Renkonen et al., 1997). To obtain
multivalent sLex polylactosaminoglycans
in reasonable amounts to study their
capability of inhibiting adhesion of
lymphocytes to endothelium, or bacteria
and viruses to host tissues in vivo, their
enzymatic in vitro synthesis should be
optimized. With the aid of recombinant
DNA technology, enzymes can be
produced in higher amounts than with
traditional purification methods from
tissues.
There are two kinds of â1,6-
GlcNAc transferases involved in in
vitro branching of polylactosamino-
glycans: distally acting â1,6-GlcNAc
transferases (dIGnT6), which catalyze
the â1,6-GlcNAc bond formation to
the peridistal galactose residue, and
centrally acting â1,6-GlcNAc
transferases (cIGnT6), which catalyze
the bond formation to the internal
galactose residues in linear
polylactosaminoglycans (for
references, see Introduction section 1.1.,
and Discussion section 5.4.) (Fig. 10).
The in vitro synthesis of multiply
branched polylactosaminoglycan chains
(reviewed in Renkonen, 2000) using
mammalian blood serum (Leppänen et
Results
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al., 1991, 1997) and human (PA1)
embryonal carcinoma cell lysates
(Leppänen et al., 1998), both of which
contain centrally acting â1,6-GlcNAc
activities, suggests that cIGnT6 rather
than dIGnT6 activity is responsible for
naturally occurring multiply branched
polylactosaminoglycans. IGnT cloned
from human PA1 cells (Bierhuizen et al.,
1993) was expressed in insect cells, and
the acceptor specificity of the recombi-
nant enzyme was evaluated in Study I.
4.1.1. Expression of human embryonal
carcinoma cell â1,6-N-acetyl-
glucosaminyltransferase in insect
cells (I)
The cDNA coding for the â1,6-GlcNAc
transferase (IGnT6) responsible for
branching of polylactosaminoglycans in
human PA1 cells has been cloned and
sequenced (Bierhuizen et al., 1993), but
the acceptor specificity of the enzyme
had not been studied. To produce pure
enzyme for in vitro specificity studies,
the cDNA encoding the soluble
ectodomain of human IGnT6 (Fig. 8L)
(amino acids 26-400) was inserted into
the pAcSecG2T baculovirus vector to
form the transfer vector pAcSecG2T-
IGnT6, which was used to transfect Sf9
insect cells. Northern blot analysis
revealed a new RNA transcript (2.3 kb) in
infected cells (I, Fig. 2A). The fusion
protein (GST-IGnT6) was detected by
Western blot analysis using a monoclonal
antibody against GST (Glutathione-S-
Transferase), which recognized bands of
67 and 74 kDa in cell lysates at 48-96
hours after infection (I, Fig. 2B). An
effective one-step purification was
carried out using affinity chromatography
with glutathione-agarose beads, which
bind to the GST moiety of the fusion
protein. Cell lysate samples were run
through the column and the protein was
eluted with glutathione. Coomassie Blue
staining after SDS-PAGE of the purified
fusion protein revealed a major band at
67 kDa (I, Fig. 4). The yield of the
recombinant fusion protein was 750 µg/
109 infected Sf9 cells in one liter of the
suspension culture.
4.1.2. Determination of the acceptor
specificity of the recombinant
GST-IGnT6 (I)
The polylactosaminoglycans used as
acceptors are presented in Table 5. The
enzymatic activity and acceptor
specificity of the recombinant GST-
IGnT6 were first studied by using Sf9
cell lysates as the enzyme source. The
radiolabeled acceptor saccharides (Table
5, glycans 1 and 2) were incubated with
the sugar nucleotide donor UDP-GlcNAc
and the cell lysate in appropriate buffer
conditions, and the reaction products
were analyzed with paper
chromatography. The acceptor
trisaccharide GlcNAcâ1-3[14C]Galâ1-
4GlcNAc (glycan 1) migrated alone,
suggesting the absence of product
saccharides (I, Fig. 5A). In contrast, the
Figure 10. Site-specificity of dis-
tally and centrally acting β1,6-N-
acetylglucosaminyltransferases.
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acceptor tetrasaccharide [14C]Galâ1-
4GlcNAcâ1-3Galâ1-4GlcNAc (glycan
2) was converted in significant amounts
into a product that migrated like a
pentasaccharide (data not shown).
The acceptor specificity of the
affinity-purified recombinant GST-
IGnT6 was studied by incubating the
fusion protein with UDP-GlcNAc and
[ 3H]Ga lâ1-4GlcNAcâ1-3Galâ1-
4GlcNAc (Table 5, glycan 2). According
to its radioactivity, the reaction mixture
contained 28% of a pentasaccharide
product, which comigrated with the
control pentasaccharide [3H]Galâ1-
4GlcNAcâ1-3(GlcNAcâ1-6)Galâ1-
4GlcNAc in paper chromatography (I,
Fig. 5B, peak 1), leaving 72% of the
acceptor tetrasaccharide (I, Fig. 5B, peak
2) unreacted.
Another reaction mixture containing
the purified GST-IGnT6 in a higher
concentration to improve the product
yield was analyzed with MALDI-TOF
mass spectrometry. The spectrum
revealed two major peaks, indicating the
presence of the pentasaccharide product
and acceptor tetrasaccharide. About half
of the tetrasaccharide was converted into
the product pentasaccharide, as
calculated from the peak intensities (I,
Fig. 6A).
Jack bean (exo)-â-galactosidase and
Bacteroides fragilis endo-â-galactosidase
digestions were performed to study the
position of the newly formed â1,6-
GlcNAc branch in the pentasaccharide
product, and the reaction products were
analyzed with paper chromatography.
Jack bean (exo)-â-galactosidase
treatment removed the tritium-labeled
galactose from the reducing end of the
pentasaccharide (I, Fig. 7A). This
suggested that the GlcNAc was not
transformed to the distal galactose
with â1,3- or â1,6-linkage. Endo-â-
galactosidase should cleave the internal
â-galactoside bond in a linear
tetrasaccharide substrate (Scudder et al.,
1984), but should not hydrolyze the
branched Galâ1-4GlcNAcâ1-
3(GlcNAcâ1-6)Galâ1-4GlcNAc
(Leppänen et al., 1997). The incubation
of the pentasaccharide with endo-â-
galactosidase did not yield any
breakdown products (I, Fig. 7B),
indicating that the GlcNAc was
transferred to the internal galactose in the
linear acceptor tetrasaccharide to form
pentasaccharide product [3H]Galâ1-
4GlcNAcâ1-3(GlcNAcâ1-6)Galâ1-
4GlcNAc.
The 1H-NMR spectrum of the product
pentasaccharide (I, Fig. 8, Table II)
showed identical structural reporter
group resonances with authentic Galâ1-
4GlcNAcâ1-3(GlcNAcâ1-6)Galâ1-
4GlcNAc (Maaheimo et al., 1997).
In conclusion, the â1,6-GlcNAc
transferase activity responsible for
branching of polylactosaminoglycans in
human PA1 cells possesses centrally
acting â1,6-GlcNAc transferase activity
rather than distally acting activity.
4.1.3. Production of multiply branched
polylactosaminoglycan using
recombinant fusion protein (I)
Tetravalent sLex glycan (Fig. 9) has been
shown to inhibit L-selectin-dependent
lymphocyte adhesion to cardiac
endothelium during acute heart transplant
rejection (Renkonen et al., 1997). In the
Stamper-Woodruff binding assay
(Stamper and Woodruff, 1976), where the
lymphocytes were preincubated with
different concentrations of tetravalent
sLex glycan, the IC50 (50% inhibitory
concentration) value was 1 nM
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(Renkonen et al., 1997). To test these
observations in vivo, larger amounts of
the multivalent sLex glycan are needed.
The capability of the recombinant fusion
protein GST-IGnT6 to branch linear
octasaccharide acceptor (Table 5, glycan
3) was studied. The incubation of the
purified recombinant fusion protein and
acceptor glycan with sugar nucleotide
donor UDP-GlcNAc resulted in a mixture
of deca- and nonasaccharide products,
and intact acceptor octasaccharide, as
shown by MALDI-TOF mass
spectrometry (I, Fig. 6B). This indicates
that the recombinant â1,6-GlcNAc
transferase is able to form multiple
branches on linear acceptor saccharide,
although the efficiency should be
improved before increasing the amount
of synthesis.
4.2. Reactivity of GalNAcâ1-4GlcNAc determinant with glycosyltransferases and
glycosidases (II)
The GalNAcâ1-4GlcNAc (lacdiNAc)
determinant replaces the nonreducing
Galâ1-4GlcNAc (lacNAc) unit in some
human and bovine glycoconjugate
glycans, and it is also common in lower
vertebrates and invertebrates (for more
detailed information, see Table 1). These
terminal lacdiNAc determinants can be
further modified similarly to their
lacNAc analogs. They can be sialylated
(Weisshaar et al., 1991; Bergwerff et al.,
1995; Dell et al., 1995), fucosylated
(Srivatsan et al., 1992; Siciliano et al.,
1993; Bergwerff et al., 1995; Dell et al.,
1995; Lochnit and Geyer, 1995), and
sulfated (Green et al., 1985; Hiyama et
al., 1992, and reviewed in Baenziger and
Green, 1988). Terminal lacdiNAc units
also serve some specific biological
functions (Smith and Baenziger, 1988;
Fiete et al., 1991; Grinnell et al., 1994;
Dell et al., 1995; Seppälä et al., 2001),
and some of them are known to be
immunogenic (Nyame et al., 1999, 2000;
van Remoortere et al., 2000, 2001). A
polylactosamine-type elongation reaction
of the lacdiNAc determinant generating
GlcNAcâ1-3GalNAcâ1-4GlcNAc-OR
has not been reported, nor has the
existence of truly internal lacdiNAc
determinants in natural polylactos-
aminoglycans.
4.2.1. Elongation of
GalNAcâ1-4GlcNAcâ1-OR
to a novel GlcNAcâ1-
3GalNAcâ1-4GlcNAcâ1-OR
determinant by enzyme activity
present in human serum (II)
Human serum contains â1,3-GlcNAc
transferase activity capable of elongating
the i-type polylactosaminoglycans
(=repeating N-acetyllactosamine units
linked together via â1,3-bonds that form
linear sugar backbone, Fig. 1) (Piller et
al., 1983; Yates and Watkins, 1983;
Hosomi et al., 1984; Seppo et al., 1990).
To study whether this enzyme activity
catalyzes the GlcNAcâ1-3GalNAc bond
formation to the distal GalNAcâ1-
4GlcNAc determinant, GalNAcâ1-
4GlcNAcâ1-OR acceptor saccharides
[Table 7, glycans 1, 9, and 14 (numbering
as in Study II, Table I)] were incubated
with UDP-GlcNAc in human serum or
human serum concentrate (Yates and
Watkins, 1983). Of glycans 1 and 9, 12-
13 mol% were converted into product
saccharides 2 and 10, respectively. In the
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case of glycan 14, where (NH4)2SO4-
concentrate of human serum was used as
an enzyme source, the product yield was
27 mol%. The MALDI-TOF mass
spectra (II, Fig. 1) of product saccharides
gave major signals that were assigned to
the molecular ions of product glycans 2,
10, and 15 (Table 7). Full assignment of
the 1H and 13C signals from various two-
dimensional spectra (II, Table III) and the
clear interglycosidic correlation in the
heteronuclear multiple bond correlation
(HMBC) spectrum (II, Fig. 3) confirmed
the positions of glycosidic linkages in
glycan 2. The correlation between the
distal e-GlcNAc H1 and the d-GalNAc
C3 (II, Fig. 3) (for monosaccharide
denotations, see Table 7) shows that the
novel â-glycosidic linkage was
GlcNAcâ1-3GalNAc. Identical two-
dimensional NMR experiments to those
of glycan 2 were performed with glycan
10, and 1H and 13C signals were assigned
(II, Table III). The data showed great
similarity between the analogous
resonances of glycans 2 and 10. The
HMBC spectrum of glycan 10 identified
the novel linkage as GlcNAcâ1-
3GalNAc (data not shown). One-
dimensional 1H-NMR spectrum of glycan
15 (II, Table IV) revealed the structural
reporter group resonances of acceptor
glycan 14 plus one equivalent resonances
at 4.574 and 4.174 ppm. Three
equivalents resonance was seen at 2.022
ppm. These resonances arose from the
distal e-GlcNAc H1, the peridistal d-
GalNAc H4, and the NAc protons
(methyl protons of N-acetyl group) of e-
GlcNAc, respectively. The reporter group
signals being identical to those of glycans
2 and 10 suggests that a distal
GlcNAcâ1-3GalNAc determinant was
also formed here.
These data imply that â1,3-GlcNAc
transferase activity present in human
serum is able to catalyze GlcNAcâ1-
3GalNAc bond formation to lacdiNAc
structure. Human serum converted only
about 12 mol% of the GalNAcâ1-
4GlcNAcâ1-OR into GlcNAcâ1-
3GalNAcâ1-4GlcNAcâ1-OR. Under
similar reaction conditions, 40-70% of i-
type polylactosaminoglycans Galâ1-
4GlcNAcâ1-OR are converted into
GlcNAcâ1-3Galâ1-4GlcNAcâ1-OR
(Leppänen et al., 1997), which suggests
that i-type polylactosaminoglycans are
better acceptors than GalNAcâ1-
4GlcNAcâ1-OR for elongation enzymes
present in human serum. In these in vitro
studies, only one acceptor saccharide was
offered to the enzyme present in human
serum. If several acceptor saccharides
had to compete against each other to be
elongated, the elongation of GalNAcâ1-
4GlcNAcâ1-OR acceptors would be less
than 12%.
4.2.2. Reactions catalyzed by
mammalian glycosyltransferases
with novel GlcNAcâ1-
3GalNAcâ1-4GlcNAcâ1-OR
acceptors (II)
An overview of the following enzymatic
reactions catalyzed by different
mammalian glycosyltransferases is
presented in Figure 11. Table I of Study
II with the numbered key
oligosaccharides is reproduced here as
Table 7 to facilitate the discussion.
Glycans 2, 10, and 15 were subjected to
enzymatic reactions that converted the
novel GlcNAcâ1-3GalNAcâ1-
4GlcNAcâ1-OR glycans into several
types of polylactosaminoglycan
analogs carrying internal lacdiNAc
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determinants. The results from these
experiments indicate that this
trisaccharide motif functions as an
acceptor for several mammalian
glycosyltransferases, which are known to
modify ordinary polylactosamino-
glycans.
4.2.2.1. â1,4-Galactosyltransferase
Bovine â1,4-galactosyltransferase has
been shown to behave flexibly with
different donor (UDP-Gal/UDP-GalNAc)
and acceptor saccharides (Palcic and
Hindsgaul, 1991). The GlcNAcâ1-
3GalNAcâ1-4GlcNAcâ1-OR glycans (2,
10, and 15) were incubated with â1,4-
galactosyltransferase and UDP-Gal. The
product saccharides (glycans 3, 11, and
17) were formed in high yields (over 90
mol%). The MALDI-TOF mass spectra
of glycans 3, 11, and 17 revealed major
signals at m/z 988.3, 826.2, and 1136.3,
respectively, which were assigned to the
acceptor glycans together with one
hexose unit. One-dimensional 1H-NMR
spectra of product glycans 3 (II, Table II),
11, and 17 (II, Table IV) contained the
reporter group resonances of the acceptor
glycans and additional H1 doublets at
4.475 ppm (in the case of glycan 3 at
4.474 ppm) arising from the novel â1,4-
linked galactose. The reactions also
caused the downfield shifts of the H1 of
the e-GlcNAc residues, seen also with
distal â1,4-galactosylation of ordinary i-
type polylactosaminoglycans (Leppänen
et al., 1997).
Glycan 2 was incubated with â1,4-
galactosyltransferase and UDP-GalNAc.
The reaction gave a product
pentasaccharide, glycan 7, in a yield
exceeding 95 mol%. The MALDI-TOF
mass spectrum of the purified glycan 7
gave a major signal, which represented
the molecular ion of Hex1HexNAc4OMe.
The one-dimensional 1H-NMR spectrum
confirmed the glycan 7 to contain two
adjacent lacdiNAc units (II, Fig. 2F,
Table II).
4.2.2.2. â1,3-Galactosyltransferase
Colon carcinoma cells (Colo 205) are
known to contain â1,4-
galactosyltransferase and â1,3-
galactosyltransferase activities (Holmes,
1989). Isshiki et al. (1999) cloned,
expressed, and characterized the â1,3-
GalT activity from Colo 205 cells and
named it â1,3Gal-T5. Glycan 2 was
incubated with Colo 205 cell lysate and
UDP-Gal in the presence of α-
lactalbumin, which inhibits â1,4-
galactosyltransferase activity of the cell
lysate against GlcNAc (Brew et al., 1968;
Schanbacher and Ebner, 1970). The
minor â1,4-galactosylated product
(glycan 3) was degraded by linkage-
specific â1,4-galactosidase from
Diplococcus pneumoniae (Hughes and
Jeanloz, 1964; Renkonen et al., 1989),
leaving the â1,3-galactosylated product
(glycan 8) intact. The resulting glycan 2
was hydrolyzed with â2,3,4,6-N-
acetylglucosaminidase from
Streptococcus pneumoniae. The MALDI-
TOF mass spectrum confirmed the
product saccharide composition to be
Hex2HexNAc3OMe. High-pH anion
exchange chromatography (HPAEC) on a
PA1 column separates slowly eluting
Galβ1-3GlcNAc isomers from faster
eluting Galβ1-4GlcNAc isomers
(Townsend et al., 1988). Glycan 8
emerged from the column at 4.77 min in
40 mM NaOH. Glycan 3 (representing
the Galβ1-4GlcNAc isomer of glycan 8)
in an identical run gave a major peak at
2.56 min. The MALDI-TOF MS and
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Figure 11. An overview of the in vitro reactions catalyzed by mammalian glycosyltransferases with acceptor saccharides containing internal lacdiNAc
determinant of Study II.
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HPAEC data together confirmed the
glycan 8 to represent a pentasaccharide
with a distal Galβ1-3GlcNAc
determinant.
4.2.2.3. â1,6-N-Acetylglucosaminyl-
transferases
Glycan 3 was incubated with UDP-
GlcNAc in a rat serum concentrate
(Leppänen et al., 1997)  containing â1,6-
N-acetylglucosaminyltransferase
activity (cIGnT6) capable of branching
ordinary i-type polylactosamino-
glycans (Gu et al., 1992; Leppänen et al.,
1997). The MALDI-TOF mass spectra
proved the reaction mixture to consist of
doubly branched glycan 6, glycans 4 and
5 carrying a single β1,6-GlcNAc branch,
and acceptor glycan 3. The structural
analysis of glycans 4, 5, and 6 was
carried out studying the 1H-NMR spectra
of glycan 6 (II, Fig. 2E, Table II), the
mixture of glycans 4 and 5 (II, Fig. 2D),
and acceptor glycan 3 (II, Fig. 2C, Table
II). Comparing these data together and to
Table 7.  Structures of the key oligosaccharides and denotations of the monosaccharide resi-
dues used in Study II (Table 1 of Study II).
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the published 1H-NMR data (Leppänen et
al., 1997; Maaheimo, 1998), the structure
of glycan 6 was interpreted to consist of
acceptor glycan 3 carrying â1,6-GlcNAc
branches at the b-Gal and at the internal
GalNAc. The mixture of glycans 4 and 5
consisted of acceptor glycan 3 carrying
a â1,6-GlcNAc branch either at the b-
Gal or at the internal GalNAc.
The purified, recombinant form of the
centrally acting â1,6-N-acetylglucos-
aminyltransferase from human PA1
cells (Study I) was used to branch glycan
11. The MALDI-TOF mass spectrum (II,
Fig. 5) consisted of two major peaks
representing the product glycan 13 and
the acceptor glycan 11. The product yield
calculated from the peak intensities was
20 mol%. When glycan 11 and control
saccharide Galâ1-4GlcNAcâ1-
3Galâ1-4GlcNAc were incubated in
similar reaction conditions, the yields
were 7 mol% and 97 mol%,
respectively (data not shown), indicating
that the lacdiNAc-containing glycan was
a poor acceptor for the recombinant
IGnT6 as compared with the control
saccharide.
Hog gastric mucosal microsomes
contain distally acting â1,6-N-
acety lg lucosaminyl - transferase
activity (Piller et al., 1984; Seppo et
al., 1990; Helin et al., 1997). Glycan 10
was incubated with UDP-GlcNAc in a
hog gastric microsome suspension. The
MALDI-TOF mass spectrum confirmed
the composition of the product to be
HexNAc4OMe. The one-dimensional
1H-NMR spectrum of glycan 12 (II,
Table IV) revealed all of the structural
reporter group resonances of the
acceptor glycan 10 and an additional
H1 doublet at 4.566/4.578 ppm that
emerged from the â1,6-linked e’-
GlcNAc-H1. In addition to the two
NAc proton singlets arising from the two
GlcNAc residues in glycan 10, the new
NAc proton resonance at a lower field
arising from â1,6-linked GlcNAc was
detected at 2.061 ppm. An almost
identical NAc proton resonance is seen
in GlcNAcâ1-3(GlcNAcâ1-6)Galâ1-
4GlcNAcâ1-OMe, which was
synthesized from GlcNAcâ1-3Galâ1-
4GlcNAcâ1-OMe in the manner
described previously (Maaheimo, 1998).
To conclude, the dIGnT activity present
in hog gastric mucosal microsomes is
able to catalyze the β1,6-branch
formation to peridistal GalNAc in
addition to peridistal Gal.
4.2.2.4. α1,3-Fucosyltransferase IV
Glycan 15 was incubated with GDP-
Fuc and partially purified recombinant
human á1,3-fucosyltransferase IV
(FucTIV) expressed in BHK-21 cells
(Grabenhorst et al., 1998). The MALDI-
TOF mass spectrum (data not shown)
revealed a major peak (88% calculated
from the peak intensities) representing a
monofucosylated reaction product
(glycan 16). A minor peak (12% from the
peak intensities) represented the
unreacted acceptor glycan 15, which was
separated from the fucosylated glycan 16
using wheat germ agglutinin (WGA)
affinity chromatography (Niemelä et al.,
1999). Glycan 16 was â1,4-
galactosylated as described for glycans 2,
10, and 15, and product glycan 18 was
subjected to further characterization. The
one-dimensional 1H-NMR spectrum of
glycan 18 (II, Table IV) revealed the
structural reporter group resonances of
glycan 17 and a fucosylated internal
lacdiNAc determinant (Bergwerff et al.,
1993). FucTIV had operated site-
specifically on the internal lacdiNAc
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unit, as indicated by the absence of the
reporter group resonances of Glc-bonded
fucose (de Vries et al., 1995), proving
that FucTIV is able to fucosylate
lacdiNAc units.
To conclude, the results from the
experiments with mammalian
glycosyltransferases revealed the first
successful enzymatic synthesis of a
GlcNAcâ1-3GalNAcâ1-4GlcNAc motif,
and that this trisaccharide motif can be
β1,4-galactosylated, β1,3-galactosylated,
β1,4-N-acetylgalactosaminylated, β1,6-
N-acetylglucosaminylated, and α1,3-
fucosylated with glycosyltransferases
known to modify ordinary mammalian
polylactosaminoglycans.
4.2.3. Enzymatic degradation of
polylactosaminoglycans
containing internal
GalNAcâ1-4GlcNAc unit (II)
Three different hydrolases were studied
to determine their capability to degrade
lacdiNAc-containing substrate
saccharides and to find a suitable method
for detection and isolation of putative
lacdiNAc analogs among naturally
occurring polylactosaminoglycans.
4.2.3.1. Endo-â-galactosidase
Glycan 11 and control oligosaccharide
Galâ1-4GlcNAcâ1-3Galâ1-4GlcNAcâ1-
3Galâ1-OMe were digested with endo-â-
galactosidase (EâG) from B. fragilis. The
MALDI-TOF mass spectrum of the
digest of glycan 11 (II, Fig. 6A) revealed
a minor peak, which represented the
breakdown product Galâ1-
4GlcNAcâ1-3GalNAc of the substrate
glycan 11. The major peak represented
the intact substrate, approximately two-
thirds of which had survived the
degradative action of the enzyme. The
control saccharide was cleaved
completely in similar reaction conditions
as seen in the MALDI-TOF mass
spectrum (II, Fig. 6B). In conclusion, the
lacdiNAc-containing glycan 11 was
cleaved slowly, being a poor substrate
for EâG.
4.2.3.2. â-Galactosidase and â-N-
acetylhexosaminidase
When glycan 17 was incubated with
jack bean exohydrolases â-
galactosidase and â-N-acetylhexos-
aminidase, it was completely
degalactosylated, as seen in MALDI-
TOF mass spectrum (II, Fig. 7A), but
only a very small fraction of it (~6% of
peak intensities) had lost GlcNAc.
Glycan 18 was digested similarly,
resulting in glycan 16 and leaving the
GlcNAcâ1-3GalNAc bond uncleaved.
The MALDI-TOF mass spectrum of a
parallel control reaction with the
heptasaccharide Galâ1-4GlcNAcâ1-
3Galâ1-4 (Fucá1-3 )GlcNAcâ1-
3Galâ1-4GlcNAc (II, Fig. 7B) revealed
a complete loss of the distal galactose
and an almost complete loss of the
subterminal â1,3-linked GlcNAc.
The results from this “double
degradation” experiment provide a
method for producing naturally occurring
lacdiNAc-containing polylactosamino-
glycans simply by degrading ordinary
ones sequentially with jack bean
exohydrolases, leaving lacdiNAc
analogs intact at the GlcNAcâ1-
3GalNAc stage.
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Yeasts have many advantages over
cultured animal cells as hosts for the
expression of recombinant proteins.
Yeasts are easy to cultivate on
inexpensive growth media, and a wide
array of techniques for genetic
manipulation of genes to be expressed is
available. Importantly, foreign proteins
can be directed by yeast-derived signal
peptides to the secretory pathway, where
posttranslational modifications take
place. If the protein being expressed is a
secretory protein, it has to be transported
through the secretory compartments to be
correctly modified. In addition, the
secretion of heterologous proteins from
yeast is desirable to simplify the
purification of the recombinant protein
since the level of endogenous secreted
proteins is quite low. And finally, many
yeasts are safe organisms, which have
been awarded the GRAS (generally
recognized as safe) status.
4.3.1. Expression of rat liver á2,3-
sialyltransferase in yeasts
Saccharomyces cerevisiae and
Pichia pastoris (III)
The catalytic ectodomain of á2,3-
sialyltransferase of rat liver (ST3Ne)
has been shown to acquire an active
and secretion-competent form in
Saccharomyces cerevisiae, but only when
fused to the Hsp150Ä carrier (Mattila et
al., 1996; Sievi et al., 1998). The
Hsp150Ä carrier is an N-terminal
fragment of a natural secretory protein
of yeast (Fig. 8A). It promotes proper
folding in the ER of heterologous
proteins fused to its C-terminus and
efficient secretion of the fusion protein
(Simonen et al., 1994, 1996; Holkeri et
al., 1996). To compare the catalytic
activity and secretion competence of the
Hsp150∆ carrier to those of the
commercially available MFá carrier,
ST3Ne was fused to the C-terminus of
both carriers (Fig. 8), and the fusion
proteins were expressed in S. cerevisiae
and P. pastoris under the control of
HSP150 and AOX1 promoters,
respectively. HSP150 is upregulated by
shift of the cells from 24°C to 37°C and
by nitrogen starvation (Russo et al.,
1993). AOX1 codes for the alcohol
oxidase, a key enzyme of the methanol
utilization pathway in methylotrophic
yeast P. pastoris, and its strong and
highly regulated promoter is induced by
methanol (Cregg et al., 1989). The fusion
proteins did not contain the Kex2p
cleavage site, resulting in the secretion of
the full-length fusion proteins. The
activity of ST3Ne was measured from the
cell lysates, the cell walls, and the culture
media after overnight cultivation. In S.
cerevisiae, 60% of the MFá-ST3Ne
activity was in the medium, 40% in the
cell wall, and virtually none inside the
cells. In the case of Hsp150Ä-ST3Ne,
more of the activity remained inside
the cells, and most of the externalized
protein stayed in the cell wall (III, Fig.
1C, a and b). In P. pastoris (III, Fig. 1C,
c and d), no significant differences were
obsereved between the carriers in the
distribution of ST3Ne activity within the
cell and the cell exterior. With both
carriers, a small amount of ST3Ne
activity remained intracellular, and most
of the secreted ST3Ne activity was cell-
wall-associated. In both yeast species,
more total activity was achieved with the
Hsp150Ä-ST3Ne fusion protein than
with MFá-ST3Ne. To conclude, both
4.3. Expression of recombinant proteins in yeasts (III, IV)
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Figure 12. Experimental setup to study the binding mechanism of the fusion proteins to S.
cerevisiae cell walls.
carriers promoted proper folding of
the catalytically active ST3Ne portion
of the fusion protein in the ER of both
yeast species.
4.3.2. Binding of fusion proteins to the
S. cerevisiae cell wall (III)
Yeast cells are surrounded by a porous
cell wall, a rigid but dynamic structure
that is essential for their viability,
providing physical and osmotic
support. The cell wall is composed of
mannoproteins (40%), â1,3-glucan
(50%), â1,6-glucan (10%), and chitin (1-
3%). The â1,3-glucan-chitin complex is
the major constituent of the inner cell
wall (Lipke and Ovalle, 1998), while the
mannoproteins reside on the outer
surface of the wall. Highly branched
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â1,6-glucan interconnects the cell wall
components, mannoproteins, â1,3-
glucan, and chitin (Kollar et al., 1997).
Hsp150Ä-ST3Ne is secreted in active,
N-glycosylated, and disulfide-bonded
form to the S. cerevisiae cell wall, to
which the de novo synthesized molecules
remain tightly bound (Mattila et al.,
1996; Sievi et al., 1998). The binding
mechanism of Hsp150∆-ST3Ne and
MFα-ST3Ne to the S. cerevisiae cell wall
was studied next. S. cerevisiae cells were
metabolically labeled, and the cell walls
were isolated. Samples consisting of
whole-cell lysates, spheroplasts, SDS
extracts of cell walls, or SDS-extracted
cell walls digested with â1,3-glucanase
(Fig. 12) were immunoprecipitated with
Hsp150 antiserum or MFá antiserum,
and the precipitates were analyzed with
SDS-PAGE (III, Fig. 2A). Both fusion
proteins were released from the cell walls
with SDS, indicating that their binding
was noncovalent.
The following reporter proteins
served as controls. Truncated Hsp150
consisting of 319 N-terminal amino acids
(Fig. 8B) is expressed mostly in secreted
form (Fatal et al., 2002), and the small
fraction remaining cell wall bound was
also released with SDS (III, Fig. 2B).
The authentic Hsp150 (Fig. 8A) was not
released with SDS, but was with â1,3-
glucanase treatment, indicating that its
binding was covalent. To conclude from
these results, the ST3Ne component was
responsible for the noncovalent binding
of the fusion proteins to the cell wall,
whereas the C-terminal domain bound
authentic Hsp150 covalently to the cell
wall.
4.3.3. Determination of the strength of
the HSP150 promoter (III)
The HSP150 promoter was studied in S.
cerevisiae by comparing its strength with
three well-known strong promoters,
namely GAL1, ADH1, and PGK1. The
HSP150 promoter provides a basal level
of expression at a physiological
temperature of 24°C and is upregulated
upon shift of the cells to a heat shock
temperature of 37°C (Russo et al., 1993).
E. coli β-lactamase fused to the
Hsp150Ä carrier (Hsp150Ä-â-
lactamase), which is rapidly secreted to
the culture medium (Simonen et al.,
1994), was used as a reporter protein. S.
cerevisiae strains expressing Hsp150Ä-
â-lactamase under the control of
promoters HSP150, GAL1, ADH1, and
PGK1 were grown overnight at 24°C to
early logarithmic growth phase. Cells
were pelleted, resuspended in fresh
medium, and the cultivation was
continued at 24°C, except for the
HSP150 promoter strain, which was
cultivated at 37°C. After 8 hours, in the
case of the HSP150 promoter, 1.5 mU/
ml of â-lactamase activity was
measured in the culture medium. For
the GAL1, ADH1, and PGK1 promoters,
2.1, 3.15, and 5.5. mU/ml of â-
lactamase activity, respectively, was in
the medium (III, Fig. 3). In all cases,
insignificant amounts of â-lactamase
activity were present in cell lysate
samples. Thus, the strength of the
HSP150 promoter at 37°C was
comparable with that of the GAL1
promoter at 24°C.
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4.3.4. Expression of Hsp150∆-FucTe in
Saccharomyces cerevisiae and
Pichia pastoris (IV)
The cDNA fragment encoding the
Hsp150∆ carrier was fused to that
encoding the catalytic ectodomain of
human α1,3-fucosyltransferase VII
(FucTe) to express Hsp150∆-FucTe (Fig.
8H). The recombinant gene was placed
under the control of the HSP150
promoter (Russo et al., 1993) and was
integrated into the genome of a S.
cerevisiae strain from which the HSP150
gene had been deleted. To study whether
Hsp150∆-FucTe was expressed, the cells
were pulse-labeled and chased. After the
pulse, a protein of 102 kDa was
immunoprecipitated with Hsp150
antiserum from the cell lysate (IV, Fig. 3,
lane 2). After a chase of 30 minutes, the
102-kDa protein had disappeared, but
two proteins of about 150 kDa and 120
kDa were detected from the cell lysate
(IV, Fig. 3, lane 4). No proteins could be
immunoprecipitated from the culture
medium (IV, Fig. 3, lanes 1 and 3). The
150-kDa protein must have been the
mature, extensively O-glycosylated
fusion protein, which remained cell wall
bound. We assume that the 102-kDa
protein was the primary O-glycosylated
form located in the ER, whose glycans
were elongated during the chase,
resulting in the 120-kDa protein.
Figure 13. Experimental setup to study the location of the fusion protein Hsp150∆-FucTe in
metabolically labeled S. cerevisiae cells.
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A P. pastoris strain was transformed
with an expression vector constructed to
produce Hsp150∆-FucTe. In this case, a
recognition site for the Golgi Kex2
protease was constructed between the
Hsp150∆ carrier and FucTe (Fig. 8I). The
chimeric gene was expressed under the
methanol-inducible AOX1 promoter in
the genome of the host strain, and the
transformants were grown for 12 days on
methanol. The cells and medium samples
were screened for expression of
Hsp150∆-FucTe by Western blotting
using Hsp150 antiserum, and the
transformant giving the strongest signal
was chosen and named P1755 (Table 6)
(data not shown).
4.3.5. Binding of Hsp150∆-FucTe to the
S. cerevisiae cell wall (IV)
To see whether Hsp150∆-FucTe
remained intracellular or was transported
to the cell wall like Hsp150∆-ST3Ne, the
S. cerevisiae strain expressing Hsp150∆-
FucTe (Table 6) was pulse-labeled and
chased for an hour. After the chase, a cell
lysate sample was immunoprecipitated
with Hsp150 antiserum directly, and a
parallel sample after proteinase K
digestion in the presence of DTT (Fig.
13). Mature Hsp150∆-FucTe of 150 kDa
was detected in the absence of proteinase
K digestion, whereas it had disappeared
after the digestion (not shown). This
implies that Hsp150∆-FucTe is located in
the cell wall and not inside the cells.
Proteinase K had destroyed the cell wall
but left the cells otherwise intact
according to the following control
experiment. Cell samples before and after
proteinase K treatment were analyzed by
Western blotting with antiserum against
cytosolic GAPDH. Similar signals were
detected, suggesting that proteinase K
had not attacked cytosolic components.
When the control experiment was
repeated using antiserum against the cell
wall protein Bgl2p, only the untreated
cell sample gave a signal, implying that
proteinase K had destroyed cell wall-
bound Bgl2p (data not shown).
Cell wall proteins of S. cerevisiae are
either covalently bound to the complex
glucose polymer β-glucan or they are
intercolocalized in the glucan layer
without covalent bonds. To study
whether the binding of Hsp150∆-FucTe
to the S. cerevisiae cell wall was covalent
or noncovalent (Fig. 12), a set of parallel
samples of S. cerevisiae cells expressing
Hsp150∆-FucTe was metabolically
labeled and chased. Immunoprecipitation
of a whole-cell sample revealed a 150-
kDa protein representing mature
Hsp150∆-FucTe (IV, Fig. 4, lane 1).
Another cell sample was subjected to the
release of the cell walls. The resulting
spheroplasts did not contain the 150-kDa
protein (IV, Fig. 4, lane 2), indicating that
the fusion protein was bound to the cell
wall. SDS extraction of the isolated cell
walls of yet another cell sample released
the 150-kDa protein (IV, Fig. 4, lane 3).
Another cell wall sample was, after SDS
extraction, digested with β1,3-glucanase
(IV, Fig. 4, lane 4), but no protein was
released. This confirms that Hsp150∆-
FucTe was bound noncovalently to the
cell wall.
4.3.6. FucTVII activity in S. cerevisiae
and P. pastoris (IV)
Next, we studied whether Hsp150∆-
FucTe expressed in S. cerevisiae and P.
pastoris was catalytically active. The
intact S. cerevisiae cells expressing
Hsp150∆-FucTe were incubated after
overnight cultivation with sialyl-lacNAc
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and GDP-[14C]Fuc. Of 200 000 cpm of
[14C]Fuc, 32 000 cpm had been
transferred to sialyl-lacNAc (data not
shown), yielding NeuNAcα2,3-
G a l β 1 , 4 ( [ 1 4C ] F u c α 1 , 3 ) G l c N A c
(radioactive sLex). In the case of the
parental strain, only 970 cpm was
transferred.
The P. pastoris strain expressing
Hsp150∆-FucTe was grown in methanol.
The FucTVII activity of the culture
medium (IV, Fig. 5, columns A),
spheroplast lysates (columns B), and
intact cells (columns C) was determined
on days 3, 6, and 9. The majority of the
FucTVII activity remained in the cell
walls throughout the cultivation, peaking
at day 9 (55 000 cpm of 200 000 cpm)
(IV, Fig. 5). Thus, Hsp150∆-FucTe was
expressed in catalytically active form in
the cell walls of S. cerevisiae and P.
pastoris.
4.3.7. Teamwork of FucTVII and ST3N
in the yeast cell wall (IV)
We next studied whether Hsp150∆-
ST3Ne and Hsp150∆-FucTe could work
in tandem to synthesize sLex from
lacNAc, CMP-NeuNAc, and GDP-
[14C]Fuc. Human fucosyltransferase VII
can transfer fucose only to α2,3-
sialylated lacNAc (Niemelä et al., 1998),
thus [14C] fucosylation implies that
sialylation has occurred first. The S.
cerevisiae strains expressing Hsp150∆-
ST3Ne and Hsp150∆-FucTe (H626 and
H649, respectively) were cultivated
overnight separately and thereafter
combined in the same test tube containing
lacNAc, CMP-NeuNAc, and GDP-
[14C]Fuc. More than 11 000 cpm (total
200 000 cpm) of radioactive glycan was
produced (IV, Fig. 6A, column a).
The S. cerevisiae strain coexpressing
Hsp150Ä-ST3Ne and Hsp150∆-FucTe
was then constructed and cultivated
overnight. When the cells were provided
with lacNAc, CMP-NeuNAc, and GDP-
[14C]Fuc, about 8500 cpm had been
transferred to lacNAc (column b). The
parental S. cerevisiae strain incubated as
above served as a negative control
(column c). The S. cerevisiae strain
expressing Hsp150∆-FucTe alone was
incubated with lacNAc and GDP-
[14C]Fuc. This experiment confirmed that
FucTVII could not fucosylate
unsialylated lacNAc (column d).
Finally, the P. pastoris strains
expressing Hsp150∆-ST3Ne and
Hsp150∆-FucTe were cultivated
separately for 7 days in methanol,
combined in the same test tube, and
incubated with lacNAc, CMP-NeuNAc,
and GDP-[14C]Fuc. Approximately, 32
000 cpm (total 200 000 cpm) of
radioactive sLex was obtained (IV, Fig.
6B, column a). Because the culture
medium of the P. pastoris strain
expressing Hsp150∆-FucTe contained
some FucTVII activity (IV, Fig. 5,
column a), P. pastoris cells expressing
Hsp150∆-ST3Ne were incubated in that
medium in the presence of lacNAc,
CMP-NeuNAc, and GDP-[14C]Fuc.
Much less radioactive sLex was
produced (column b) than above,
consistent with the notion that most of
the fusion proteins remained in the cell
wall. The negative control experiments
were carried out as described above for
S. cerevisiae (columns c and d).
To conclude, ectodomains of
human fucosyltrasferase VII and rat
á2,3-sialyltransferase functioned in
tandem in the cell wall of intact yeast
cells, synthesizing sLex from CMP-
NeuNAc, GDP-[14C]Fuc, and lacNAc
(IV, Fig. 7).
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5. DISCUSSION
5.1. Use of mammalian glycosyltransferases
5.1.1. Substrate specificity of
recombinant β1,6-N-
acetylglucosaminyltransferase
The i- and I-blood group antigens are
glycan structures that are characterized
by linear and branched repeats of N-
acetyllactosamine, respectively, and they
are present on various glycolipids and
glycoproteins (Fig. 1) (Feizi et al., 1979;
Fukuda et al., 1979; Koscielak et al.,
1979; Watanabe et al., 1979). The
expression of i- and I-antigens is
developmentally regulated, and structural
changes in these carbohydrates are also
seen in cell differentiation and
malignancy (reviewed in Leppänen,
1997). Because of the building block, N-
acetyllactosamine, they are also referred
to as lactosaminoglycans. The linear i-
type blood group antigen is synthesized
by sequential action of â1,3-N-
acetylglucosaminyltransferase and
â1,4-galactosyltransferase. It has long
been suspected that a precursor-
product relationship exists between i-
and I-antigens and that the synthesis of
branched I-type glycan would require
yet another enzymatic activity, that of
I-branching â1,6-N-acetylglucos-
aminyltransferase (IGnT) (Fukuda et
al., 1979; Koscielak et al., 1979; Piller et
al., 1984). â1,6-N-acetylglucos-
aminyltransferase has been identified
in microsomal preparations from hog
gastric mucosal microsomes, and this
enzyme activity catalyzes the reaction
GlcNAcâ1-3Galâ1-4GlcNAc + UDP-
GlcNAc →  GlcNAcâ1-3(GlcNAcâ1-
6)Galâ1-4GlcNAc (Piller et al., 1984),
thus representing distally acting IGnT6
transferase (dIGnT) (Fig. 10) (Piller et
al., 1984; Brockhausen et al., 1986;
Koenderman et al., 1987; Seppo et al.,
1990; Gu et al., 1992; Helin et al., 1997).
â1,6-N-acetylglucosaminyltransferase
activity, which functions as a centrally
acting branching enzyme (cIGnT) (Fig.
10), was described in 1991 (Leppänen et
al., 1991). Human (Leppänen et al.,
1991), as well as bovine, equine, rat, and
ovine (Leppänen et al., 1997), sera
contain â1,6-GlcNAc-transferase
activities, which catalyze multiple
branching to internal galactose
residues of a linear polylactosamino-
glycan backbone, as confirmed with
degradative experiments, MALDI-
TOF mass spectrometry, and NMR
spectroscopy (Leppänen et al., 1997).
The cDNA encoding IGnT was first
cloned from human embryonal
carcinoma cells (PA1 cells) (Bierhuizen
et al., 1993), which are known to contain
large amounts of polylactosaminoglycans
covalently bound to proteins (Rasilo et
al., 1980; Rasilo and Renkonen, 1982;
Fukuda et al., 1985), as well as cIGnT
rather than dIGnT activity (Leppänen et
al., 1998). The cDNA codes for a type II
transmembrane protein, and when
expressed in Chinese hamster ovary cells
(CHO), which normally express only
linear i-antigens (Sasaki et al., 1987;
Smith et al., 1990), the cells acquired I-
branched polylactosaminoglycan
structures (Bierhuizen et al., 1993). In
Study I, the catalytic ectodomain of this
enzyme was fused to GST, the
recombinant fusion protein was
expressed in Sf9 insect cells, and the
acceptor specificity of the fusion
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protein was examined. The
recombinant protein catalyzed the
transfer of GlcNAc from UDP-
GlcNAc to the linear tetrasaccharide
Galâ1-4GlcNAcâ1-3Galâ1-4GlcNAc
(Table 5, glycan 2) to position 6 of the
underlined Gal residue, as confirmed by
mass spectrometry, degradative
experiments, and 1H-NMR
spectroscopy. The recombinant
protein did not, however, react with
UDP-GlcNAc and trisaccharide
acceptor GlcNAcâ1-3Galâ1-4GlcNAc
(Table 5, glycan 1), indicating the need
for the presence of at least one
complete LacNAc unit bonded to
position 3 of the reacting galactose
residue. When the recombinant IGnT6
was incubated with the octasaccharide
(Galâ1-4GlcNAc)4 (Table 5, glycan 3),
the MALDI-TOF mass spectrum of the
product glycan confirmed that two
additional HexNAc units had been
added. Thus, the recombinant enzyme
could form multiple branches on a
preformed i-type polylactosaminoglycan
chain. Taken together, Sf9 insect cells as
an expression system provides the means
to produce functional glycosyl-
transferases, and the cDNA isolated from
human embryonal carcinoma cells of line
PA1 (Bierhuizen et al., 1993) codes for
centrally acting â1,6-GlcNAc
transferase activity.
To date, three centrally acting human
IGnT activities have been cloned and
characterized, namely IGnT1, IGnT2,
and IGnT3. IGnT1 stands for the enzyme
described above, and it was the first one
to be cloned and characterized
(Bierhuizen et al., 1993 and Study I). All
three isoforms consist of 3 exons and
share the second and third exons (Inaba
et al., 2003; Yu et al., 2003). They are
considered to be generated by alternative
splicing of a single gene. Transcripts of
IGnT1 and IGnT2 show similar tissue
distribution. The expression pattern of
IGnT3, by contrast, is clearly different.
Bone marrow cells preferentially express
the IGnT3 transcript. This transcript is
present in reticulocytes, but not in fetal
liver (Inaba et al., 2003; Yu et al., 2003),
suggesting that the biosynthesis of I-
blood group antigens in terminally
differentiated erythrocytes results from
IGnT3 activity.
The naturally occurring polylactos-
aminoglycans usually consist of a long
main chain with several short branches
(Fukuda, 1985). cIGnT activities have
been suggested to be responsible for the
multiple short branches in I-antigens
(Leppänen et al., 1997). If dIGnT activity
was responsible for the multiple
branching, acting coordinately with
â1,4-GalT and â1,3-GlcNAcT,
branched branches would predominate
over short branches. The recombinant
IGnT described in Study I helps to
synthesize multiply branched glycans,
which can be modified further to carry
multivalent sLex sequences. These
structures have been shown to be
nanomolar inhibitors of L-selectin-
mediated adhesion of lymphocytes to
activated endothelium (Renkonen et al.,
1997), and their synthesis is described in
detail elsewhere (Renkonen et al., 1997;
Salminen et al., 1997).
5.1.2. Elongation of GalNAcâ1-
4GlcNAcâ1-OR to a novel
GlcNAcâ1-3GalNAcâ1-
4GlcNAcβ1-OR
Polylactosaminoglycans consist of
repeating lacNAc units joined by â1,3-
linkages. They can be â1,6-branched,
and the linear backbones as well as the
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branches are the carriers of the
terminal structures, which participate
in biological activities of
glycoconjugates. However, in a
number of glycoconjugates studied so
far, the lacdiNAc determinant
(GalNAcâ1-4GlcNAc) replaces the
terminal lacNAc unit (Table 1). This
terminal lacdiNAc unit can be decorated
with different capping monosaccharides
similar to their ordinary lacNAc-
containing analogs (reviewed in van den
Eijnden et al., 1997). The differently
modified lacdiNAc units can have
immunogenic properties (Nyame et al.,
1999, 2000; van Remoortere et al., 2000,
2001), and they are suspected of
modifying the biological activities of the
glycoconjugates carrying them (Smith
and Baenziger, 1988; Fiete et al., 1991;
Grinnell et al., 1994; Dell et al., 1995).
However, truly internal lacdiNAc units
in naturally occurring polylactos-
aminoglycans have not been reported,
although GlcNAcâ1-3GalNAc linkage
is encountered in the core 3 structure of
O-glycans (Fig. 2) (Brockhausen et al.,
1985) and in Schistosoma mansoni
glycolipids (Wuhrer et al., 2000). Here,
â1,3-N-acetylglucosaminyltransferase
activity present in human serum (Piller
and Cartron, 1983; Yates and Watkins,
1983; Hosomi et al., 1984; Seppo et al.,
1990) catalyzed the formation of
GlcNAcâ1-3GalNAc linkage between
the incoming GlcNAc monosaccharide
and the terminal lacdiNAc
determinant in acceptor saccharides of
type GalNAcâ1-4GlcNAcâ1-OR. This
novel, internal lacdiNAc determinant
was identified by NMR data, which
included long-range correlations in
heteronuclear multiple bond correlation
spectra. The yields were, however,
considerably lower (12.5 mol%) than
those obtained before using acceptor
saccharides presenting solely lacNAc
units in their backbones (40-70 mol%)
(Leppänen et al., 1997). Here, the
reaction conditions were optimized to
favor bond formation. The conditions
were not competitive since only
lacdiNAc-containing acceptor
saccharides were present. As some
purified glycosyltransferases are truly
multifunctional, such as sialyl-α2,3-
transferase, also known as ST3Gal II,
which transfers sialic acid efficiently to
Gal and GalNAc (Toivonen et al., 2001),
we thought that the same enzyme activity
present in human serum is in our in vitro
experiments responsible for elongating
both lacNAc- and lacdiNAc-terminating
acceptors. Furthermore, to favor product
formation, the acceptor and donor sugar
concentrations were kept high to force
the reaction to proceed forward (0.24
mM acceptor saccharide, 4.8 mM UDP-
GlcNAc).
As the reaction conditions in vivo
differ dramatically from those of our in
vitro experiments described above,
internal lacdiNAc units may not be as
abundant in human polylactosamino-
glycans. One of our findings could assist
in enriching and characterizing these
structures in naturally occurring
polylactosaminoglycans. The
sequential action of two degradative
enzymes, namely jack bean â-
galactosidase and â-N-acetylhexos-
aminidase, hydrolyzes ordinary,
desialylated, and defucosylated poly-
lactosaminoglycans monosaccharide
by monosaccharide (Niemelä et al.,
1998). In polylactosaminoglycans
containing internal lacdiNAc units, the
action of degradative enzymes stops at
the GlcNAcâ1-3GalNAcâ1-
4GlcNAcâ1-OR stage, as we have
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shown in Study II. Thus, this
degradative treatment identifies internal
lacdiNAc unit-containing polylactos-
aminoglycans among ordinary ones,
providing a means to study their
occurrence.
As shown in Figure 11, the synthetic
GlcNAcâ1-3GalNAcâ1-4GlcNAcâ1-
OR saccharides proved to be
functional acceptors for enzyme-
assisted â1,3-galactosylation, â1,4-
galactosylation, â1,4-N-acetylgalactos-
aminylation, á1,3-fucosylation, and
several â1,6-N-acetylglucos-
aminylation reactions catalyzed by
mammalian glycosyltransferases
known to function with ordinary
polylactosaminoglycans. The reactions
catalyzed by â1,3-galactosyltransferase
(Colo 205 cell lysate) (Holmes, 1989),
distally acting â1,6-N-acetyl-
glucosaminyltransferase (hog gastric
mucosal microsomes) (Piller et al.,
1984; Seppo et al., 1990; Helin et al.,
1997), and centrally acting â1,6-N-
acetylglucosaminyltransferase (rat
serum) (Gu et al., 1992; Leppänen et al.,
1997) were carried out with crude
enzyme preparations. Hence, determining
whether the same enzyme activity or two
different activities are responsible for
catalyzing the reactions with lacNAc-
and lacdiNAc-containing acceptor
glycans is not possible. Data from our
experiments, nevertheless, imply that this
trisaccharide motif functions as an
acceptor for several pure glycosyl-
transferases or crude glycosyltransferase
preparations that modify natural
mammalian polylactosaminoglycans.
To summarize, polylactosamino-
glycanbranching enzyme (IGnT6) cloned
from human embryonal carcinoma cells
(PA1) was expressed in insect cells, and
its acceptor specificity was studied. It
showed catalytic activity towards internal
Gal residues along the linear poly-
lactosaminoglycan, thus exhibiting
centrally acting branching activity
(cIGnT6). The recombinant enzyme
could catalyze the formation of multiple
branches on a linear, preformed acceptor
glycan, which is the first step in the
synthesis of multivalent binding
inhibitors of leukocyte adhesion.
We also showed that enzyme activity
present in human serum could elongate
the acceptor glycans containing terminal
lacdiNAc. A novel GlcNAcβ1-
3lacdiNAc linkage was formed that
generated an internal lacdiNAc
determinant, a determinant that has not
been encountered in naturally occurring
polylactosaminoglycans. These novel
glycans functioned as acceptors for
mammalian glycosyltransferases, and in
addition, a method was developed for
searching for naturally occurring internal
lacdiNAc determinants.
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5.2. Production of mammalian glycosyltransferases in yeast
5.2.1. Hsp150Ä carrier functions in
expression of rat á2,3-
sialyltransferase in
Saccharomyces cerevisiae and
Pichia pastoris
The Hsp150Ä carrier polypeptide,
which is an N-terminal fragment of a
natural secretory glycoprotein of
Saccharomyces cerevisiae (Russo et al.,
1992), functions in production of
heterologous proteins in S. cerevisiae by
conferring proper folding and secretion
competence (Simonen et al., 1994, 1996;
Jämsä et al., 1995; Holkeri et al., 1996;
Mattila et al., 1996; Sievi et al., 1998).
The catalytic ectodomain of rat á2,3-
sialyltransferase (ST3Ne) has
previously been expressed in yeast S.
cerevisiae fused to the Hsp150Ä carrier
polypeptide, and the fusion protein
was externalized but remained bound to
the cell wall. This made it possible to use
whole yeast cells as an enzyme source for
sialylation of glycans and asialo-
glycoproteins (Mattila et al., 1996; Sievi
et al., 1998).
The cell wall association of the fusion
protein Hsp150∆-ST3Ne was
noncovalent, as it could be released
with SDS, not needing â1,3-glucanase
treatment (III). The ST3Ne portion was
thought to be responsible for the
attachment of the fusion protein to the
cell wall because the authentic Hsp150
binds covalently (also shown by Kapteyn
et al., 1999) and Hsp150∆ as such is
secreted to the culture medium (Fatal et
al., 2002).
The performance of the Hsp150Ä
carrier in Pichia pastoris was studied
next and compared with that of the
MFá carrier in both S. cerevisiae and P.
pastoris. The MFá carrier is
commercially available and widely
used. It is the prepro-region of the yeast
S. cerevisiae mating factor á (Fig. 6)
(Kurjan and Herskowitz, 1982; Brake et
al., 1983; Julius et al., 1983). The use of
the methylotrophic yeast P. pastoris as an
expression system is attractive when high
product levels are desired. The
expression system is based on strong,
regulated promoters derived from
methanol metabolism pathway genes
(Fig. 7). This system is commercially
available as a kit and has a number of
biotechnological applications (Gellissen,
2000; Lin Cereghino and Cregg, 2000).
The efficiency of the Hsp150Ä
carrier in S. cerevisiae and P. pastoris in
expression of ST3Ne in catalytically
active form was at least as high as that of
the MFα carrier (III, Fig. 1C). The
Hsp150Ä carrier was also functional
under the control of the alcohol oxidase
promoter (AOX) in P. pastoris. Thus, this
carrier appears to be as effective as the
MFα carrier in promoting the proper
folding and transport of catalytically
active ST3Ne in the ER of S. cerevisiae
and P. pastoris.
The catalytic ectodomain of rat α2,6-
sialyltransferase (ST6Ne) has also been
expressed as a Hsp150∆ fusion protein
(Hsp150∆-ST6Ne). The ST6Ne portion
of Hsp150∆-ST6Ne acquired a
catalytically active conformation in the
ER and was transported to the Golgi
apparatus. But instead of being
externalized, the fusion protein was
targeted to the vacuole and degraded
there. The signal guiding the fusion
protein to destruction was speculated to
reside in the ST6Ne portion because the
Hsp150∆ fusion proteins have been
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considered to be stable (Sievi et al.,
2001).
5.2.2 Strenght of the HSP150 promoter
is comparable with that of GAL1
Efficient transcription of foreign genes is
achieved with promoters of yeast origin,
while the use of foreign promoters does
not result in accurate initiation of
transcription (Romanos et al., 1992). We
compared the strength of the HSP150
promoter with that of three well-known
strong promoters of S. cerevisiae, namely
the GAL1, ADH1, and PGK1 promoters.
The HSP150 promoter, derived from the
HSP150 gene of S. cerevisiae, was
cloned and characterized in our
laboratory (Russo et al., 1992). It is
upregulated by heat and nutrient stress
(Russo et al., 1993). The HSP150 5’-
flanking region contains three heat shock
elements (HSE) (Russo et al., 1992).
Site-directed mutagenesis of one of these
elements located between the TATA box
and the transcription initiation site
abolished heat activation of transcription
(Russo et al., 1993). Here, the strength of
the HSP150 promoter was found to be
comparable with that of the GAL1
promoter. The ADH1 and PGK1
promoters, which belong to the glycolytic
promoters of S. cerevisiae, were shown to
be considerably stronger (3.15 U/ml and
5.5 U/ml, respectively) than HSP150 and
GAL1 promoters (1.5 U/ml and 2.1 U/ml,
respectively), but their disadvantage lies
in their nonregulated nature (Romanos et
al., 1992). This makes them a poor
promoter choice when the growth stage
needs to be separated from the expression
stage (e.g. with toxic products) or when
dealing with large-scale cultures. The
HSP150 promoter is simply activated by
shifting the cells from a physiological
temperature of 24-30°C to 37°C. To
activate the GAL1 promoter, one needs to
change the carbon source of the culture
medium from glucose to galactose.
Comparing the strengths of the GAL1
and HSP150 promoters, we paid attention
to cell densities. The optical density
(OD600) of the HSP150 strain was twice
as high as that of the GAL1 promoter
strain (III, Fig. 3). If the production of
the reporter protein were dependent on
the concentration of the cells in the
culture, the GAL1 promoter would have
been two times stronger than the HSP150
promoter.
5.2.3. Expression of the catalytic
ectodomain of human á1,3-
fucosyltransferase VII in S.
cerevisiae and P. pastoris
Lymphocyte extravasation into the
inflamed tissue is initiated by interactions
between L-selectin and their counter
receptors on endothelial cells, which
carry sLex tetrasaccharide epitopes
[NeuNAcá2-3Galâ1-4(Fucá1-3)GlcNAc]
in response to inflammatory stimuli
(Turunen et al., 1994, 1995). In an organ
transplant, this infiltration of
lymphocytes to the graft is not desirable.
The tetravalent sLex glycan (Fig. 9) has
been shown to efficiently inhibit
lymphocyte adhesion to the endothelium
in vitro (Renkonen et al., 1997),
suggesting that this glycan can be used as
an anti-inflammatory drug. To produce
recombinant human α1,3-fucosyl-
transferase VII for sLex synthesis, we
transformed S. cerevisiae and P. pastoris
with chimeric genes that encoded the
fusion protein Hsp150∆-FucTe (Fig. 8H
and 8I) under the control of the HSP150
and AOX1 promoters, respectively. Yeast
was chosen as the host organism because
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it lacks endogenous sLex-synthesizing
transferases and is capable of modifying
proteins with, for example, a disulfide
bond. In addition, it is able to secrete
proteins and can be grown to high cell
densities in inexpensive media. In both
yeast species, the Hsp150Ä carrier
succeeded in guiding the fusion
proteins through the secretory
pathway. Most of the FucTe activity
remained bound to the cell wall, which
enabled whole yeast cells to be used as
an enzyme source. The recombinant S.
cerevisiae and P. pastoris strains were
able to synthesize sLex from sialyl-α2,3-
N-acetyllactosamine and GDP-Fuc.
5.2.4. Teamwork of FucTVII and ST3N
in the yeast cell wall
We also used yeast strains expressing
the catalytic ectodomain of rat á2,3-
sialyltransferase (ST3Ne) and FucTe
combined to synthesize sLex from
lacNAc, CMP-NeuNAc, and GDP-Fuc.
The yeast strains were cultivated
separately overnight and then added to
the same test tube. The product yields
were too low (picomole scale) for
determination of the linkage position or
the α/â-anomericity. The cDNA
coding for the secretory FucTVII has
also been expressed in a B-cell
lymphoma cell line (Shinoda et al.,
1997) and in baculovirus-infected insect
cells (Shinkai et al., 1997). In both cases,
the recombinant proteins showed α1,3-
fucosyltransferase activity toward
terminally α2,3-sialylated lacNAc.
Hsp150Ä-ST3Ne expressed in S.
cerevisiae is known, according to
degradative experiments and 1H-NMR, to
catalyze the transfer of sialic acid in
α2,3-linkage to lacNAc (Mattila et al.,
1996). Human fucosyltransferase VII
efficiently fucosylates only sialylated
type 2 oligosaccharides (Natsuka et al.,
1994; Sasaki et al., 1994; Shinoda et al.,
1997; Niemelä et al., 1998), forming
tetrasaccharide sLex but not trisaccharide
Lex. Our control experiments with
lacNAc and GDP-Fuc confirmed that
Hsp150∆-FucTe utilized only sialylated
lacNAc as an acceptor. In conclusion, the
catalytic ectodomain of human
fucosyltransferase VII expressed in yeast
transferred fucose to α2,3-sialylated
lacNAc, probably with an α1,3-linkage.
Both S. cerevisiae and P. pastoris have
previously been used to produce
glycosyltransferases. The cDNA from
HeLa cells coding for the full-length
membrane-bound form of β1,4-
galactosyltransferase (β1,4-GalT) has
been expressed in S. cerevisiae (Krezdorn
et al., 1993). The enzyme activity of the
recombinant â1,4-GalT could be
detected in crude cell lysates. Using N-
acetylglucosamine or glucose as
acceptors in combination with á-
lactalbumin, the enzyme catalyzed the
formation of the â1,4-bond between
galactose and N-acetylglucosamine or
glucose, as estimated with 1H-NMR
analysis (Krezdorn et al., 1993). Full-
length human á2,6-sialyltransferase
expressed in S. cerevisiae (Krezdorn et
al., 1994) catalyzed the expected á2,6-
linkage between sialic acid and
acceptors asialofetuin and N-
acetyllactosamine, as confirmed with
1H-NMR. However, due to the absence of
hyperglycosylation and the Man-α1,6-
Man epitope, two posttranslational
modifications normally carried out in the
Golgi apparatus, both β1,4-
galactosyltransferase and α2,6-
sialyltransferase were speculated to have
stayed in the ER in enzymatically active
form (Krezdorn et al., 1994). Sievi et al.
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(2001) reported the expression in S.
cerevisiae of the catalytic ectodomain of
rat α2,6-sialyltransferase (ST6Ne) fused
to the Hsp150∆ carrier. Hsp150∆-ST6Ne
was catalytically active and reached the
Golgi compartment. But instead of being
externalized, the fusion protein was
transported from the Golgi to the vacuole
for destruction. The loss of enzymatic
activity of the newly synthesized protein
occurred within one hour (Sievi et al.,
2001). Because Hsp150, the Hsp150∆
carrier, and Hsp150∆-ST3Ne are
externalized (Russo et al., 1992; Jämsä et
al., 1995; Mattila et al., 1996), the signal
targeting Hsp150∆-ST6Ne to the vacuole
was thought to reside in the ST6Ne
portion (Sievi et al., 2001).
As the purification of membrane-
bound proteins is difficult and time-
consuming, the sequences coding for
the N-terminal cytoplasmic and
transmembrane domains of human
â1,4-GalT have been replaced by the
yeast invertase signal peptide (Kleene et
al., 1994). The catalytic ectodomain of
human â1,4-GalT acquired a
catalytically active form in S. cerevisiae
in the absence of a carrier polypeptide.
The enzymatic activity could be
recovered from cell lysates with
ultracentrifugation, indicating the
presence of a cell-associated soluble
protein (Kleene et al., 1994). The
fermentation technology of S. cerevisiae
enabled large-scale production of
heterologous glycosyltransferase in
bioreactors larger than 100 liters (Borsig
et al., 1995; Herrmann et al., 1995b).
G. Herrmann and his colleagues
realized that in addition to the cell-
associated soluble β1,4-GalT the cell
walls of intact yeast cells contained 31.5
mU/(g wet cells) β1,4-GalT-activity. For
comparison, after disintegration of the
cells, soluble β1,4-GalT-activity in yeast
cell lysates was 68.1 mU/(g wet cells)
(Herrmann et al., 1995a). They used
intact yeast cells in the synthesis of N-
acetyllactosamine from GlcNAc and
UDP-Gal to avoid cell lysis and
centrifugation. The whole yeast cells
could be lyophilized and reused with no
detectable loss of β1,4-GalT-activity and
without the need to purify the
recombinant glycosyltransferases.
Separation of the product from the
transferase was done simply by pelleting
the cells (Herrmann et al., 1995a).
Among human fucosyltransferases,
α1,3-fucosyltransferase III and α1,3-
fucosyltransferase VI have been
expressed in yeast. Abe et al. (2004)
fused the ectodomain of human α1,3-
fucosyltransferase VI to full-length
Hsp150 (also called Pir2p) and detected
FucTVI activity in the S. cerevisiae cell
wall. The ectodomain of FucTVI has
been expressed in P. pastoris with the aid
of the S. cerevisiae-derived MFα signal
peptide, and one liter of shake flask
culture produced 3 U of the enzyme in
the medium (Malissard et al., 2000). The
ectodomain of FucTIII fused to the
prepro-fragment of MFα was expressed
in P. pastoris. The activity was initially in
the cell wall (Lubineau et al., 1998), but
after 7 days of fed-batch fermentation,
the majority of the enzymatic activity
was in the culture medium, and 11.3 units
of the enzyme could be harvested from
one liter (Gallet et al., 1998).
In conclusion, rat α2,3-
sialyltransferase and human α1,3-
fucosyltransferase VII were expressed in
the yeasts S. cerevisiae and P. pastoris.
Their ectodomains were fused to the
Hsp150∆ and MFα carriers. Both carriers
effectively promoted the proper folding
of the catalytic ectodomains in S.
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cerevisiae and P. pastoris. The fusion
proteins were secreted but remained
bound to the yeast cell wall, which
enabled the use of intact yeast cells as a
source of enzymatic activity. Yeasts
expressing the two enzymes either in
separate strains or in a single strain
functioned in tandem, and the intact yeast
cells synthesized sLex from lacNAc,
CMP-NeuNAc, and GDP-Fuc. The
recombinant proteins in S.cerevisiae
were expressed under the control of the
HSP150 promoter, the strength of which
was comparable with that of the GAL1
promoter.
Discussion
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